# REPUBLIC OF SOUTH AFRICA

# GOVERNMENT GAZETTE

# STAATSKOERANT

## VAN DIE REPUBLIEK VAN SUID-AFRIKA

*Registered at the Post Office as a Newspaper* *As 'n Nuusblad by die Poskantoor Geregistreer*

**Price 20c Prys**
**Overseas 30c Oorsee**
**POST FREE—POSVRY**

VOL. 112] CAPE TOWN, 30 OCTOBER 1974 [No. 4469
KAAPSTAD, 30 OKTOBER 1974

### DEPARTMENT OF THE PRIME MINISTER

No. 2000. 30 October 1974.

It is hereby notified that the State President has assented to the following Act which is hereby published for general information:—

No. 65 of 1974: Drugs Control Amendment Act, 1974.

### DEPARTEMENT VAN DIE EERSTE MINISTER

No. 2000. 30 Oktober 1974.

Hierby word bekend gemaak dat die Staatspresident sy goedkeuring geheg het aan die onderstaande Wet wat hierby ter algemene inligting gepubliseer word:—

No. 65 van 1974: Wysigingswet op die Beheer van Medisyne, 1974.

Wet No. 65, 1974 WYSIGINGSWET OP DIE BEHEER VAN MEDISYNE, 1974.

# WET

**Tot wysiging van die Wet op die Beheer van Medisyne, 1965, ten einde sekere uitdrukkings te vervang of te omskryf of nader te omskryf; in die Engelse teks die benaming „drug" deur die benaming „medicine" te vervang en sekere teksveranderings aan te bring wat voortspruit uit bedoelde vervanging; die beheer oor medisyne verder te reël; die samestelling van die Medisynebeheerraad en die besoldiging van die lede daarvan, van die lede van die komitees daarvan en van die lede van die Appèlraad op Medisynebeheer verder te reël; voorsiening te maak vir beheer oor gelyste stowwe; nuwe voorsiening te maak vir inspekteurs, ontleders, farmakoloë en patoloë wat nodig geag word vir die behoorlike uitvoering van genoemde Wet; en 'n verandering aan te bring met betrekking tot die bevoegdheid om regulasies uit te vaardig; en om voorsiening te maak vir aangeleenthede wat daarmee in verband staan.**

(*Engelse teks deur die Staatspresident geteken.*)
(*Goedgekeur op* 23 *Oktober* 1974.)

DAAR WORD BEPAAL deur die Staatspresident, die Senaat en die Volksraad van die Republiek van Suid-Afrika, soos volg:—

Vervanging van artikel 1 van Wet 101 van 1965.

**1.** (1) Artikel 1 van die Wet op die Beheer van Medisyne, 1965, (hieronder die Hoofwet genoem), word hierby deur die volgende artikel vervang:

„Woordomskrywing.

**1.** (1) Tensy uit die samehang anders blyk, beteken in hierdie Wet—

(i) ‚advertensie', met betrekking tot medisyne of 'n gelyste stof, enige skriftelike, geïllustreerde, visuele of ander beskrywende stof of mondelinge verklaring of verwysing—

(*a*) wat in 'n nuusblad of ander publikasie verskyn; of

(*b*) wat onder lede van die publiek versprei word; of

(*c*) wat op enige wyse hoegenaamd onder die aandag van lede van die publiek gebring word,

en wat bedoel is om die verkoop van daardie medisyne of gelyste stof te bevorder; en het ‚adverteer' 'n ooreenstemmende betekenis; (i)

(ii) ‚appèlraad' die Appèlraad op Medisynebeheer by artikel 10 ingestel; (iii)

(iii) ‚apteker' iemand wat kragtens die Wet op Aptekers, 1974, as sodanig geregistreer is; (xvii)

(iv) ‚Aptekersraad' die Suid-Afrikaanse Aptekersraad bedoel in artikel 2 van die Wet op Aptekers, 1974; (xix)

(v) ‚as geneesmiddel', met betrekking tot 'n gelyste stof, tot behandeling of voorkoming van 'n siekte of met 'n ander bepaalde genesende of terapeutiese doel, maar nie ook die bevrediging

# ACT

**To amend the Drugs Control Act, 1965, so as to replace or define or further define certain expressions; to substitute the appellation "medicine" for the appellation "drug" in the English text, and to effect certain textual changes in that text arising out of such substitution; to further regulate the control of medicines; to further regulate the constitution of the Medicines Control Council and the remuneration of its members, of the members of its committees and of the members of the Medicines Control Appeal Board; to provide for the control of Scheduled substances; to make new provision for inspectors, analysts, pharmacologists and pathologists considered necessary for the proper enforcement of the said Act; and to effect a change in relation to the power to make regulations; and to provide for matters connected therewith.**

(*English text signed by the State President.*)
(*Assented to* 23 *October* 1974.)

BE IT ENACTED by the State President, the Senate and the House of Assembly of the Republic of South Africa, as follows:—

Substitution of section 1 of Act 101 of 1965.

**1.** (1) The following section is hereby substituted for section 1 of the Drugs Control Act, 1965 (hereinafter referred to as the principal Act):

"Definitions. **1.** (1) In this Act, unless the context otherwise indicates—

(i) 'advertisement', in relation to any medicine or Scheduled substance, means any written, pictorial, visual or other descriptive matter or verbal statement or reference—
(*a*) appearing in any newspaper or other publication; or
(*b*) distributed to members of the public; or
(*c*) brought to the notice of members of the public in any manner whatsoever,
which is intended to promote the sale of that medicine or Scheduled substance; and 'advertise' has a corresponding meaning; (i)

(ii) 'analyst' means an analyst to whom authority has been granted under section 27; (xxix)

(iii) 'appeal board' means the Medicines Control Appeal Board established by section 10; (ii)

(iv) 'approved name', in relation to a medicine, means the internationally recognized name of such medicine or such other name as the council may determine, not being a brand name or trade name registered in terms of the Trade Marks Act, 1963 (Act No. 62 of 1963); (xxi)

(v) 'council' means the Medicines Control Council established by section 2; (xxxii)

(vi) 'dentist' means a person registered as such under the Medical Act; (xxxvii)

**Wet No. 65, 1974** WYSIGINGSWET OP DIE BEHEER VAN MEDISYNE, 1974.

Vervanging van artikel 14 van Wet 101 van 1965, soos vervang deur artikel 1 van Wet 29 van 1968.

**12.** (1) Artikel 14 van die Hoofwet word hierby deur die volgende artikel vervang:

„Verbod op verkoop van medisyne wat aan registrasie onderhewig is en nie geregistreer is nie.

**14.** (1) Behoudens die bepalings van hierdie artikel of artikels 21 en 22A, mag niemand enige medisyne wat aan registrasie onderhewig is uit hoofde van 'n besluit ingevolge subartikel (2) van hierdie artikel gepubliseer, verkoop nie tensy dit geregistreer is.

(2) (*a*) Die raad kan van tyd tot tyd by besluit deur die Minister goedgekeur, bepaal dat 'n in die besluit vermelde medisyne of klas of kategorie van medisyne of gedeelte van 'n klas of kategorie van medisyne aan registrasie ingevolge hierdie Wet onderhewig is.

(*b*) So 'n besluit kan ook betrekking hê slegs op medisyne wat onmiddellik voor die datum waarop dit ingevolge paragraaf (*c*) in werking tree in die Republiek of die gebied vir verkoop beskikbaar was, of slegs op medisyne wat nie toe aldus beskikbaar was nie.

(*c*) So 'n besluit moet deur die registrateur in die *Staatskoerant* gepubliseer word en tree in werking op die datum waarop dit aldus gepubliseer word.

(3) In die geval van medisyne wat onmiddellik voor die datum van publikasie in die *Staatskoerant* van die besluit uit hoofde waarvan dit aan registrasie ingevolge hierdie Wet onderhewig is, in die Republiek of die gebied vir verkoop beskikbaar was, tree die bepalings van subartikel (1) in werking—

(*a*) indien daar nie binne die tydperk van ses maande onmiddellik na daardie datum om registrasie van daardie medisyne aansoek gedoen word nie, by verstryking van daardie tydperk; of

(*b*) indien daar binne daardie tydperk om die registrasie van bedoelde medisyne aansoek gedoen word, op die datum een maand na die datum waarop 'n kennisgewing met betrekking tot die medisyne ingevolge artikel 15 (10) of artikel 17 (*a*) in die *Staatskoerant* gepubliseer word.

(4) Die bepalings van subartikel (1) is nie van toepassing nie ten opsigte van die verkoop van enige medisyne wat deur 'n geneesheer in die loop van die verrigting van sy professionele bedrywighede aangemaak word vir 'n bepaalde persoon in 'n hoeveelheid nie groter nie as die hoeveelheid nodig vir behandeling soos deur die geneesheer bepaal of deur 'n apteker aangemaak word vir 'n bepaalde persoon in 'n hoeveelheid nie groter nie as dié wat normaalweg nodig is vir die doel waarvoor dit verkoop word, of in 'n hoeveelheid vir 'n bepaalde persoon soos deur 'n geneesheer of tandarts voorgeskryf, indien sodanige medisyne nie 'n bestanddeel bevat waarvan die verkoop deur hierdie Wet verbied word of 'n bestanddeel ten opsigte waarvan 'n aansoek om registrasie van die hand gewys is nie, en nie geadverteer word of is nie.

(5) Die bepalings van subartikel (4) is, met ingang van die datum waarop alle medisyne aan registrasie onderhewig word uit hoofde van besluite ingevolge subartikel (2) gepubliseer, nie van toepassing op enige medisyne nie tensy die aktiewe bestanddele van sodanige medisyne ingevolge hierdie Wet geregistreer is.".

**12.** (1) The following section is hereby substituted for section 14 of the principal Act: Substitution of section 14 of Act 101 of 1965, as substituted by section 1 of Act 29 of 1968.

"Prohibition on the sale of medicines which are subject to registration and are not registered.

**14.** (1) Save as provided in this section or sections 21 and 22A, no person shall sell any medicine which is subject to registration by virtue of a resolution published in terms of subsection (2) unless it is registered.

(2) (*a*) The council may from time to time by resolution approved by the Minister, determine that a medicine or class or category of medicines or part of any class or category of medicines mentioned in the resolution shall be subject to registration in terms of this Act.

(*b*) Any such resolution may also relate only to medicines which were available for sale in the Republic or the territory immediately prior to the date on which it comes into operation in terms of paragraph (*c*) or only to medicines which were not then so available.

(*c*) Any such resolution shall be published in the *Gazette* by the registrar and shall come into operation on the date on which it is so published.

(3) In the case of a medicine which was available for sale in the Republic or the territory immediately prior to the date of publication in the *Gazette* of the resolution by virtue of which it is subject to registration in terms of this Act, the provisions of subsection (1) shall come into operation—

(*a*) if no application for the registration of such medicine is made within the period of six months immediately succeeding that date, on the expiration of that period; or

(*b*) if application for the registration of such medicine is made within the said period, on the date one month after the date on which a notice in respect of such medicine is published in the *Gazette* in terms of section 15 (10) or section 17 (*a*).

(4) The provisions of subsection (1) shall not apply in respect of the sale of any medicine compounded in the course of carrying on his professional activities by a medical practitioner for a particular person in a quantity not greater than the quantity required for treatment as determined by the medical practitioner or compounded by a pharmacist for a particular person in a quantity not greater than that normally required for the purpose for which it is sold or in a quantity for a particular person as prescribed by a medical practitioner or a dentist, if such medicine does not contain any component the sale of which is prohibited by this Act or any component in respect of which an application for registration has been rejected, and is not and has not been advertised.

(5) The provisions of subsection (4) shall, with effect from the date upon which all medicines become subject to registration by virtue of resolutions published in terms of subsection (2), not apply to any medicine unless the active components of such medicine have been registered under this Act.".

(8) Geen voorwaardes word ingevolge subartikel (7) opgelê nie waarby die verkoop van die betrokke medisyne deur iemand anders as 'n apteker verbied word of voordat die applikant skriftelik deur die registrateur in kennis gestel is dat die oplegging van bedoelde voorwaarde beoog word en uitgenooi is om skriftelike vertoë in verband met die saak aan die raad voor te lê.

(9) Indien sodanige vertoë nie binne een maand nadat hy 'n in subartikel (8) bedoelde kennisgewing ontvang het deur die applikant by die registrateur ingedien word nie, of indien die raad na oorweging van sodanige vertoë nog van oordeel is dat die betrokke voorwaarde opgelê behoort te word, gelas die raad die registrateur om die betrokke medisyne onderworpe aan daardie voorwaarde te registreer.

(10) Die registrateur moet in die *Staatskoerant* kennis gee dat 'n aansoek ingevolge hierdie artikel ten opsigte van medisyne in subartikel (3) van artikel 14 bedoel, van die hand gewys is—

(*a*) indien daar nie binne die in artikel 24 voorgeskrewe tydperk teen die vandiehandwysing appèl aangeteken word nie, so spoedig moontlik na die verstryking van daardie tydperk; of

(*b*) indien 'n aldus aangetekende appèl afgewys word, so spoedig moontlik nadat die beslissing waarby die appèl afgewys word, gegee is.

(11) Die registrateur moet so spoedig moontlik na die datum van verstryking van die toepaslike tydperk in subartikel (3) van artikel 14 bedoel, die voorgeskrewe besonderhede ten opsigte van alle aansoeke om registrasie wat hy voor daardie datum ontvang het in die *Staatskoerant* publiseer.".

Wysiging van artikel 16 in Engelse teks van Wet 101 van 1965, soos gewysig deur artikel 3 van Wet 29 van 1968.

**14.** Artikel 16 van die Hoofwet word hierby gewysig deur in die Engelse teks die woord „drug", waar dit ook al voorkom, deur die woord „medicine" te vervang.

Vervanging van artikel 17 van Wet 101 van 1965, soos gewysig deur artikel 4 van Wet 29 van 1968.

**15.** Artikel 17 van die Hoofwet word hierby deur die volgende artikel vervang:

„Bekendmaking van registrasie of intrekking van registrasie in *Staatskoerant*.

**17.** Die registrateur moet in die *Staatskoerant* kennis gee van die registrasie of intrekking van die registrasie van enige medisyne ingevolge hierdie Wet, en moet in sodanige kennisgewing vermeld—

(*a*) in die geval van 'n registrasie van 'n medisyne, die naam waaronder sodanige medisyne geregistreer is, die aktiewe bestanddele van sodanige medisyne, die naam van die persoon wat aansoek om die registrasie van sodanige medisyne gedoen het, die nommer daaraan toegewys ingevolge artikel 15 en die voorwaardes (as daar is) waaraan die registrasie onderworpe gestel is;

(*b*) in die geval van 'n intrekking van die registrasie van 'n medisyne, die naam waaronder sodanige medisyne geregistreer was, die naam van die persoon wat om die registrasie van sodanige medisyne aansoek gedoen het en die nommer wat ingevolge artikel 15 daaraan toegewys was.".

(8) No condition shall be imposed under subsection (7) whereby the sale of the medicine in question by any person other than a pharmacist is prohibited or until after the applicant has in writing been notified by the registrar that the imposition of such condition is contemplated and invited to submit written representations to the council in regard to the matter.

(9) If no such representations are lodged with the registrar by the applicant concerned within a period of one month after the receipt by him of any notification referred to in subsection (8), or if after consideration of any such representations the council is still of the opinion that the condition in question should be imposed, the council shall direct the registrar to register the relevant medicine subject to the said condition.

(10) Notice of the rejection of an application under this section in respect of a medicine referred to in subsection (3) of section 14 shall be given in the *Gazette* by the registrar—

(*a*) if no appeal is lodged against the rejection within the period prescribed in section 24, as soon as possible after the expiration of that period; or

(*b*) if any appeal so lodged is dismissed, as soon as possible after the decision dismissing the appeal has been given.

(11) The registrar shall as soon as possible after the date of expiry of the appropriate period referred to in subsection (3) of section 14 publish in the *Gazette* the prescribed particulars in respect of all applications for registration received by him prior to such date.".

Amendment of section 16 of Act 101 of 1965, as amended by section 3 of Act 29 of 1968.

**14.** Section 16 of the principal Act is hereby amended by the substitution for the word "drug", wherever it occurs, of the word "medicine".

Substitution of section 17 of Act 101 of 1965, as amended by section 4 of Act 29 of 1968.

**15.** The following section is hereby substituted for section 17 of the principal Act:

"Notification of registration or cancellation of registration in *Gazette*.

**17.** The registrar shall give notice in the *Gazette* of the registration or cancellation of the registration of any medicine in terms of this Act, and shall in such notice specify—

(*a*) in the case of a registration of any medicine, the name under which such medicine is registered, the active components of such medicine, the name of the person who applied for the registration of such medicine, the number allocated to it in terms of section 15 and the conditions (if any) subject to which it is registered;

(*b*) in the case of a cancellation of the registration of any medicine, the name under which such medicine was registered, the name of the person who applied for the registration of such medicine and the number which was allocated to it in terms of section 15.".

**Wet No. 65, 1974** WYSIGINGSWET OP DIE BEHEER VAN MEDISYNE, 1974.

Vervanging van artikel 18 van Wet 101 van 1965.

**16.** Artikel 18 van die Hoofwet word hierby deur die volgende artikel vervang:

„Etikette en advertensies.

**18.** (1) Niemand mag medisyne of 'n gelyste stof verkoop nie, tensy die pakket waarin daardie medisyne of gelyste stof verkoop word 'n etiket aan het waarop vermeld word—

(*a*) die goedgekeurde naam van daardie medisyne en onmiddellik daarna, in die geval van geregistreerde medisyne, die nommer ingevolge artikel 15 daaraan toegewys, wat, indien daar 'n handelsnaam of die naam van die fabrikaat op die etiket voorkom, onmiddellik bo bedoelde handelsnaam of naam van die fabrikaat moet voorkom en in letters moet wees wat nie kleiner is as die helfte van die grootte van die letters wat vir bedoelde handelsnaam of naam van die fabrikaat gebruik word nie en wat in alle ander opsigte nie minder opvallend as bedoelde handelsnaam of naam van die fabrikaat moet wees nie; en

(*b*) die aktiewe bestanddele van bedoelde medisyne of gelyste stof volgens massa of volgens volume of volgens eenhede, onmiddellik voor of na bedoelde goedgekeurde naam.

(2) Niemand mag medisyne skriftelik vir verkoop adverteer nie, tensy—

(*a*) die goedgekeurde naam van daardie medisyne en onmiddellik daarna, in die geval van geregistreerde medisyne, die nommer ingevolge artikel 15 daaraan toegewys, in die advertensie vermeld word, en wel (indien die handelsnaam of die naam van die fabrikaat van die medisyne, ook in die advertensie vermeld word) onmiddellik bo daardie handelsnaam of naam van die fabrikaat waar dit die eerste maal gebesig word en in letters nie kleiner nie as die helfte van die grootte van die letters wat vir daardie handelsnaam of naam van die fabrikaat gebruik word en sodat dit in alle ander opsigte nie minder opvallend as bedoelde handelsnaam of naam van die fabrikaat is nie; en

(*b*) die name, soos deur die raad bepaal, van die aktiewe bestanddele van die medisyne en die massa of volume of getal eenhede van sodanige bestanddele onmiddellik voor of na die goedgekeurde naam of na bedoelde nommer vermeld word.

(3) Die bepalings van subartikel (1) is nie van toepassing nie ten opsigte van die verkoop van medisyne wat—

(*a*) deur 'n geneesheer vir die behandeling van 'n bepaalde persoon verkoop word en deur dié geneesheer aan of ten behoewe van daardie persoon verskaf word, indien sodanige geneesheer meen dat die aanbring van die voorgeskrewe besonderhede op die etiket nie in die belang van sodanige persoon is nie; of

(*b*) deur 'n apteker vir die behandeling van 'n bepaalde persoon verkoop word en deur daardie apteker aan of ten behoewe van bedoelde persoon verskaf word ooreenkomstig 'n voorskrif deur 'n geneesheer gegee indien sodanige geneesheer die voorskrif met die woorde „non nomen" geëndosseer het en sodanige endossement geparafeer het; of

(*c*) indien sodanige medisyne 'n gedeelte is van die oorspronklike inhoud van 'n pakket wat ooreenkomstig die bepalings van hierdie Wet

**16.** The following section is hereby substituted for section 18 of the principal Act: Substitution of section 18 of Act 101 of 1965.

"Labels and advertisements.

**18.** (1) No person shall sell any medicine or Scheduled substance unless the package in which such medicine or Scheduled substance is sold bears a label stating—

(*a*) the approved name of that medicine immediately followed, in the case of a registered medicine, by the number allocated thereto under section 15, which shall, if any trade name or brand name appears on the label, appear immediately above such trade name or brand name and shall be in letters not less than half the size of the letters in which such trade name or brand name appears and shall in all other respects be not less conspicuous than such trade name or brand name; and

(*b*) the active components of such medicine or Scheduled substance by mass or by volume or by unit immediately before or after the said approved name.

(2) No person shall in writing advertise any medicine for sale, unless—

(*a*) the approved name of such medicine, immediately followed, in the case of a registered medicine, by the number allocated thereto in terms of section 15, is stated in the advertisement, and (if the trade name or brand name, of the medicine is also stated in the advertisement) appears immediately above such trade name or brand name where it is used for the first time and is in letters not less than half the size of the letters in which such trade name or brand name appears and is in all other respects not less conspicuous than such trade name or brand name; and

(*b*) the names, as determined by the council, of the active components of the medicine and the mass or volume or number of units of such components are stated immediately before or after the approved name or after such number.

(3) The provisions of subsection (1) shall not apply in respect of the sale of any medicine—

(*a*) sold by a medical practitioner for the treatment of a particular person and supplied by such medical practitioner to or on behalf of such person, if such medical practitioner considers that it would not be in the interest of such person for the prescribed particulars to appear on the label; or

(*b*) sold by a pharmacist for the treatment of a particular person and supplied to or on behalf of such person by such pharmacist in accordance with a prescription given by a medical practitioner if such medical practitioner has endorsed the prescription with the words "non nomen" and initialled such endorsement; or

(*c*) if such medicine forms a portion of the original contents of a package which is labelled in accordance with the provisions of this Act and

geëtiketteer is, deur 'n apteker of geneesheer of tandarts uit sodanige pakket geneem en deur sodanige apteker, geneesheer of tandarts of ten behoewe van 'n hospitaal verkoop word vir die behandeling van 'n bepaalde persoon en wat aan of ten behoewe van sodanige persoon verskaf word in 'n pakket wat 'n etiket aan het waarop vermeld word—

(i) die naam en adres van sodanige apteker, geneesheer, tandarts of hospitaal;

(ii) in die geval van geregistreerde medisyne, die nommer ingevolge artikel 15 aan sodanige medisyne toegewys;

(iii) die naam van die medisyne;

(iv) aanwysings (as daar is) van die wyse waarop sodanige medisyne gebruik behoort te word; en

(v) die naam van die persoon vir wie se behandeling sodanige medisyne verkoop word.".

Wysiging van artikel 19 in Engelse teks van Wet 101 van 1965.

**17.** Artikel 19 van die Hoofwet word hierby gewysig deur in die Engelse teks die woord „drug", waar dit ook al voorkom, deur die woord „medicine" te vervang.

Wysiging van artikel 20 in Engelse teks van Wet 101 van 1965.

**18.** Artikel 20 van die Hoofwet word hierby gewysig deur in die Engelse teks die woord „drug", waar dit ook al voorkom, deur die woord „medicine" te vervang.

Wysiging van artikel 21 in Engelse teks van Wet 101 van 1965.

**19.** Artikel 21 van die Hoofwet word hierby gewysig deur in die Engelse teks die woord „drug", waar dit ook al voorkom, deur die woord „medicine" te vervang.

Vervanging van artikel 22 van Wet 101 van 1965.

**20.** Artikel 22 van die Hoofwet word hierby deur die volgende artikel vervang:

„Raad moet sekere inligting aan geneeshere, tandartse en aptekers verstrek.

**22.** Die raad moet, onderworpe aan die goedkeuring van die Sekretaris, en op die wyse wat die raad die geskikste ag—

(*a*) so spoedig doenlik nadat 'n medisyne geregistreer is, geneeshere, tandartse, aptekers en die persoon wat aansoek om die registrasie van sodanige medisyne gedoen het, verwittig van—

(i) die naam en nommer waaronder sodanige medisyne geregistreer is en die voorwaardes (as daar is) waaraan die medisyne se registrasie onderworpe gestel is;

(ii) die terapeutiese doeltreffendheid en effek van sodanige medisyne;

(iii) die doel waarvoor, die omstandighede waaronder en die wyse waarop sodanige medisyne gebruik behoort te word; en

(iv) enige ander aangeleentheid betreffende sodanige medisyne wat, na die mening van die raad, vir hulle van waarde kan wees;

(*b*) so spoedig doenlik nadat die registrasie van 'n medisyne ingevolge artikel 16 ingetrek is, geneeshere, tandartse, aptekers en die persoon wat aansoek om die registrasie van sodanige medisyne gedoen het van die intrekking van sodanige registrasie verwittig.".

such medicine is taken by a pharmacist or medical practitioner or dentist from such package and is sold by such pharmacist, medical practitioner or dentist or on behalf of a hospital for the treatment of a particular person and is supplied to or on behalf of such person in a package which bears a label stating—

(i) the name and address of such pharmacist, medical practitioner, dentist or hospital;

(ii) in the case of a registered medicine, the number allocated to such medicine in terms of section 15;

(iii) the name of the medicine;

(iv) directions (if any) in regard to the manner in which such medicine should be used; and

(v) the name of the person for whose treatment such medicine is sold.".

Amendment of section 19 of Act 101 of 1965.

**17.** Section 19 of the principal Act is hereby amended by the substitution for the word "drug" wherever it occurs of the word "medicine".

Amendment of section 20 of Act 101 of 1965.

**18.** Section 20 of the principal Act is hereby amended by the substitution for the word "drug" wherever it occurs of the word "medicine".

Amendment of section 21 of Act 101 of 1965.

**19.** Section 21 of the principal Act is hereby amended by the substitution for the word "drug" wherever it occurs of the word "medicine".

Substitution section 22 of Act 101 of 1965.

**20.** The following section is hereby substituted for section 22 of the principal Act:

"Council to furnish certain information to medical practitioners, dentists and pharmacists.

**22.** The council shall, subject to the approval of the Secretary, in such manner as it considers most suitable—

(*a*) as soon as practicable after any medicine has been registered, inform medical practitioners, dentists, pharmacists and the person who applied for the registration of such medicine—

(i) of the name and number under which such medicine is registered and the conditions, if any, subject to which such medicine is registered;

(ii) of the therapeutic efficacy and effect of such medicine;

(iii) of the purpose for which, the circumstances under which and the manner in which such medicine should be used; and

(iv) regarding any other matter concerning such medicine which, in the opinion of the council, may be of value to them;

(*b*) as soon as practicable after the registration of any medicine has been cancelled in terms of section 16, inform medical practitioners dentists, pharmacists and the person who applied for the registration of such medicine of the cancellation of such registration.".

Wet No. 65, 1974 WYSIGINGSWET OP DIE BEHEER VAN MEDISYNE, 1974.

Invoeging van artikel 22A in Wet 101 van 1965.

**21.** Die volgende artikel word hierby in die Hoofwet na artikel 22 ingevoeg:

„Beheer oor medisyne en gelyste stowwe.

**22A.** (1) Behoudens die bepalings van hierdie artikel, mag niemand 'n medisyne of gelyste stof verkoop nie tensy hy die houer van 'n lisensie is wat ingevolge 'n ordonnansie van 'n provinsiale raad of die gebied op die voorgeskrewe voorwaardes uitgereik is of hy in diens by die houer van so 'n lisensie is: Met dien verstande dat hierdie artikel nie uitgelê word nie asof dit van 'n geneesheer, tandarts, apteker of veearts vereis dat hy so 'n lisensie moet besit om 'n medisyne of gelyste stof in die loop van die wettige verrigting van sy professionele bedrywighede te verkoop.

(2) Die lisensie-owerheid kan en moet op aanbeveling van die raad te eniger tyd 'n ingevolge so 'n ordonnansie uitgereikte lisensie intrek, opskort of beperk indien daar aan so 'n voorwaarde waarop sodanige lisensie uitgereik is, nie voldoen word nie.

(3) 'n Bylae 1-stof, behalwe so 'n stof wat vir die doeleindes van hierdie subartikel voorgeskryf word, mag nie deur die houer van 'n in subartikel (1) bedoelde lisensie verkoop word nie: Met dien verstande dat enige Bylae 1-stof nie aan iemand wat oënskynlik minder as sestien jaar oud is, verkoop mag word nie behalwe op 'n voorskrif uitgereik deur 'n geneesheer, tandarts of veearts en toeberei deur 'n apteker, kwekeling-apteker of ongekwalifiseerde assistent of deur 'n geneesheer of tandarts of veearts of op 'n skriftelike bestelling waaruit blyk vir watter gebruik bedoelde stof bestem is en waarop 'n handtekening voorkom wat aan die verkoper bekend is as die handtekening van iemand wat die verkoper ken en wat oënskynlik meer as sestien jaar oud is, en daardie bestelling moet deur die verkoper bewaar word vir 'n tydperk van minstens ses maande na die betrokke verkoop.

(4) 'n Bylae 2-stof mag nie verkoop word nie—

(*a*) deur iemand anders as 'n apteker of 'n kwekeling-apteker of ongekwalifiseerde assistent handelende onder die persoonlike toesig van 'n apteker; en

(*b*) aan iemand wat oënskynlik minder as sestien jaar oud is, behalwe op 'n voorskrif uitgereik deur 'n geneesheer, tandarts of veearts en toeberei deur 'n apteker, kwekeling-apteker of ongekwalifiseerde assistent of deur 'n geneesheer of tandarts of veearts of op 'n skriftelike bestelling waaruit blyk vir watter gebruik bedoelde stof bestem is en waarop 'n handtekening voorkom wat aan die verkoper bekend is as die handtekening van iemand wat die verkoper ken en wat oënskynlik meer as sestien jaar oud is; en

(*c*) tensy die verkoper in 'n voorskrifboek wat op die voorgeskrewe wyse gehou moet word, al die voorgeskrewe besonderhede van bedoelde verkoop opteken.

(5) 'n Bylae 3-stof mag nie verkoop word nie—

(*a*) deur iemand anders as 'n apteker of 'n kwekeling-apteker of ongekwalifiseerde assistent handelende onder die persoonlike toesig van 'n

**21.** The following section is hereby inserted in the principal Act after section 22: Insertion of section 22A in Act 101 of 1965.

"Control of medicines and Scheduled substances.

**22A.** (1) Subject to the provisions of this section, no person shall sell any medicine or Scheduled substance unless he is the holder of a licence issued in terms of an ordinance of a provincial council or the territory on the prescribed conditions, or he is employed by the holder of any such licence: Provided that nothing in this subsection contained shall be construed as requiring a medical practitioner, dentist, pharmacist or veterinarian to hold any such licence to sell any medicine or Scheduled substance in the course of lawfully carrying on his professional activities.

(2) The licensing authority may, and shall on the recommendation of the council, at any time withdraw, suspend or restrict any licence issued in terms of any such ordinance if any such condition on which such licence has been issued, is not complied with.

(3) Any Schedule 1 substance, not being any such substance prescribed for the purposes of this subsection, shall not be sold by thel hoder of a licence referred to in subsection (1): Provided that any Schedule 1 substance shall not be sold to any person apparently under the age of sixteen years except upon a prescription issued by a medical practitioner, dentist or veterinarian and dispensed by a pharmacist, trainee pharmacist or unqualified assistant or by a medical practitioner or dentist or veterinarian or on a written order which discloses the purpose for which such substance is to be used and bears a signature known to the seller as the signature of a person known to such seller and who is apparently over the age of sixteen years, and such order shall be retained by such seller for a period of not less than six months after the relevant sale.

(4) Any Schedule 2 substance shall not be sold—

(*a*) by any person other than a pharmacist or a trainee pharmacist or unqualified assistant acting under the personal supervision of a pharmacist; and

(*b*) to any person apparently under the age of sixteen years except upon a prescription issued by a medical practitioner, dentist or veterinarian and dispensed by a pharmacist, trainee pharmacist or unqualified assistant or by a medical practitioner or dentist or veterinarian or on a written order which discloses the purpose for which such substance is to be used and bears a signature known to the seller as the signature of a person known to such seller and who is apparently over the age of sixteen years; and

(*c*) unless the seller enters in a prescription book required to be kept in the prescribed manner, all the prescribed particulars of such sale.

(5) Any Schedule 3 substance shall not be sold—

(*a*) by any person other than a pharmacist or a trainee pharmacist or unqualified assistant acting under the personal supervision of a

apteker, op 'n skriftelike voorskrif uitgereik deur 'n geneesheer, tandarts of veearts of ingevolge mondelinge opdrag van 'n geneesheer, tandarts of veearts wat aan daardie apteker bekend is; of

(*b*) aan iemand anders as 'n geneesheer, tandarts, veearts of apteker; en

(*c*) tensy die verkoper in 'n voorskrifboek wat op die voorgeskrewe wyse gehou moet word, al die voorgeskrewe besonderhede van bedoelde verkoop op die voorgeskrewe wyse opteken; en

(*d*) in die geval van 'n verkoop soos bepaal in paragraaf (*a*), in 'n groter hoeveelheid as dié vermeld in die in daardie paragraaf bedoelde voorskrif of opdrag: Met dien verstande dat bedoelde verkoop op daardie voorskrif of opdrag vir gebruik ingevolge daardie voorskrif of opdrag, herhaal kan word gedurende 'n tydperk van hoogstens ses maande vanaf die datum van die eerste sodanige verkoop.

(6) 'n Bylae 4-stof mag nie verkoop word nie—

(*a*) deur iemand anders as 'n apteker of 'n kwekeling-apteker of ongekwalifiseerde assistent handelende onder die persoonlike toesig van 'n apteker, op 'n skriftelike voorskrif van 'n geneesheer, tandarts of veearts of ingevolge mondelinge opdrag van 'n geneesheer, tandarts of veearts wat aan daardie apteker bekend is: Met dien verstande dat 'n geneesheer, tandarts of veearts wat so 'n mondelinge opdrag gegee het, binne sewe dae nadat hy die opdrag gegee het, aan die apteker 'n skriftelike voorskrif, by wyse van bevestiging van bedoelde opdrag, moet verstrek; of

(*b*) aan iemand anders as 'n geneesheer, tandarts, veearts of apteker; en

(*c*) tensy die verkoper in 'n voorskrifboek wat op die voorgeskrewe wyse gehou moet word, al die voorgeskrewe besonderhede van bedoelde verkoop op die voorgeskrewe wyse opteken; en

(*d*) in die geval van 'n verkoop op 'n skriftelike voorskrif soos bepaal in paragraaf (*a*), in 'n groter hoeveelheid as dié vermeld in die voorskrif: Met dien verstande dat, indien die persoon wat die voorskrif uitgereik het, daarop aangedui het hoeveel maal en met watter tussenpose dit toeberei kan word, bedoelde verkoop dienooreenkomstig herhaal kan word: Met dien verstande voorts dat elke verkoper die datum van verkoop en die hoeveelheid van genoemde stof wat verkoop is, op die voorskrif moet aanteken en dat die laaste verkoper die voorskrif moet behou vir 'n tydperk van minstens drie jaar vanaf die datum van die laaste verkoop.

(7) (*a*) Behalwe vir sover deur die bepalings van hierdie subartikel veroorloof, mag niemand 'n Bylae 5-stof gebruik of besit of vervaardig nie, of 'n plant of deel daarvan waaruit so 'n stof afgetrek, verkry, voortgebring of vervaardig kan word, insamel, kweek of aanhou nie.

pharmacist, upon a written prescription issued by a medical practitioner, dentist or veterinarian or on the verbal instructions of a medical practitioner, dentist or veterinarian who is known to such pharmacist; or

(*b*) to any person other than a medical practitioner, dentist, veterinarian or pharmacist; and

(*c*) unless the seller enters in the prescribed manner in a prescription book required to be kept in the prescribed manner, all the prescribed particulars of such sale; and

(*d*) in the case of a sale as provided in paragraph (*a*), in a quantity greater than that stated in the prescription or instructions referred to in that paragraph: Provided that such sale may, upon such prescription or instructions, be repeated for use in terms of such prescription or instructions during a period not exceeding six months as from the date of the first such sale.

(6) A Schedule 4 substance shall not be sold—

(*a*) by any person other than a pharmacist or a trainee pharmacist or unqualified assistant acting under the personal supervision of a pharmacist, upon a written prescription of a medical practitioner, dentist or veterinarian or on the verbal instructions of a medical practitioner, dentist or veterinarian who is known to such pharmacist: Provided that a medical practitioner, dentist or veterinarian who has given such verbal instructions shall within seven days after giving such instructions furnish to such pharmacist a written prescription confirming such instructions; or

(*b*) to any person other than a medical practitioner, dentist, veterinarian or pharmacist; and

(*c*) unless the seller enters in the prescribed manner in a prescription book required to be kept in the prescribed manner, all the prescribed particulars of such sale; and

(*d*) in the case of a sale on a written prescription as provided in paragraph (*a*), in a quantity greater than that stated in the prescription: Provided that such sale may, if the person who issued the prescription indicated thereon the number of times and the intervals at which it may be dispensed, be repeated accordingly: Provided further that every seller shall endorse on the prescription the date of sale and the quantity of the said substance sold, and that the last seller shall retain the prescription for a period of not less than three years as from the date of the last sale.

(7) (*a*) Save as is permitted by the provisions of this subsection, no person shall use or have in his possession or manufacture any Schedule 5 substance, or collect, cultivate or keep any plant or portion thereof from which any such substance can be extracted, derived, produced or manufactured.

(*b*) 'n Bylae 5-stof mag nie verkoop word nie—

(i) deur iemand anders as 'n apteker of 'n kwekeling-apteker of ongekwalifiseerde assistent handelende onder die persoonlike toesig van 'n apteker, op 'n skriftelike voorskrif van 'n geneesheer, tandarts of veearts; of

(ii) aan iemand anders as 'n geneesheer, tandarts, veearts of apteker; en

(iii) tensy die verkoper in 'n voorskrifboek wat op die voorgeskrewe wyse gehou moet word, al die voorgeskrewe besonderhede van bedoelde verkoop op die voorgeskrewe wyse opteken; en

(iv) in die geval van 'n verkoop soos bepaal in subparagraaf (i), in 'n groter hoeveelheid as dié vermeld in die voorskrif: Met dien verstande dat, indien die persoon wat die voorskrif uitgereik het, daarop aangedui het hoeveel maal en met watter tussenpose dit toeberei kan word, bedoelde verkoop dienooreenkomstig herhaal kan word: Met dien verstande voorts dat elke verkoper die datum van verkoop en die hoeveelheid van genoemde stof wat verkoop is, op die voorskrif moet aanteken en dat die laaste verkoper die voorskrif moet behou vir 'n tydperk van minstens drie jaar vanaf die datum van die laaste verkoop.

(*c*) 'n Bylae 5-stof mag nie behalwe as geneesmiddel toegedien of gebruik word nie: Met dien verstande dat die Minister magtiging kan verleen, onderworpe aan voldoening aan die voorwaardes of vereistes in so 'n magtiging vermeld, vir die toediening buite 'n hospitaal of inrigting bedoel in die omskrywing van „as geneesmiddel" in artikel 1, van so 'n stof vir die bevrediging of verligting van 'n gewoonte of drang na die toegediende stof of na 'n ander sodanige stof, aan die bepaalde persoon in die magtiging vermeld.

(*d*) 'n Bylae 5-stof mag nie vervaardig of by die groot maat verkoop of ingevoer of uitgevoer word nie tensy die voorgeskrewe aantekenings met betrekking daartoe op die voorgeskrewe wyse gehou word.

(*e*) Die Sekretaris kan op aanbeveling van die raad en onderworpe aan die voorwaardes en vereistes wat die Sekretaris op daardie aanbeveling bepaal, aan iemand 'n permit uitreik om so 'n stof te verkry, besit of gebruik, of om 'n plant of deel daarvan waaruit so 'n stof afgetrek, verkry, voortgebring of vervaardig kan word, of vir wetenskaplike, navorsings-, analitiese of opvoedkundige doeleindes, in te samel, te kweek of aan te hou.

(8) (*a*) Behalwe vir sover deur die bepalings van hierdie subartikel veroorloof, mag niemand 'n Bylae 6-stof gebruik of besit of vervaardig nie, of 'n plant of deel daarvan waaruit so 'n stof afgetrek, verkry, voortgebring of vervaardig kan word, insamel, kweek of aanhou nie.

(*b*) A Schedule 5 substance shall not be sold—

(i) by any person other than a pharmacist or a trainee pharmacist or unqualified assistant acting under the personal supervision of a pharmacist, upon a written prescription of a medical practitioner, dentist or veterinarian; or

(ii) to any person other than a medical practitioner, dentist, veterinarian or pharmacist; and

(iii) unless the seller enters in the prescribed manner in a prescription book required to be kept in the prescribed manner, all the prescribed particulars of such sale; and

(iv) in the case of a sale as provided in subparagraph (i), in a quantity greater than that stated in the prescription: Provided that such sale may, if the person who issued the prescription indicated thereon the number of times and the intervals at which it may be dispensed, be repeated accordingly: Provided further that every seller shall endorse on the prescription the date of sale and the quantity of the said substance sold, and that the last seller shall retain the prescription for a period of not less than three years as from the date of the last sale.

(*c*) A Schedule 5 substance shall not be administered or used for other than medicinal purposes: Provided that the Minister may grant authority, subject to compliance with such conditions or requirements as may be stated in such authority, for the administration outside any hospital or institution referred to in the definition of 'medicinal purpose' in section 1, of any such substance for the satisfaction or relief of a habit or craving for the substance administered or for any other such substance, to the particular person referred to in such authority.

(*d*) A Schedule 5 substance shall not be manufactured or sold by wholesale or imported or exported unless the prescribed records relating thereto are kept in the prescribed manner.

(*e*) The Secretary may, on the recommendation of the council, issue, subject to such conditions and requirements as the Secretary may on such recommendation determine, a permit to any person to acquire, possess or use any such substance, or to collect, cultivate or keep any plant or any portion thereof from which any such substance may be extracted, derived, produced or manufactured or for scientific, research, analytical or educational purposes.

(8) (*a*) Save as is permitted by the provisions of this subsection, no person shall use or have in his possession or manufacture any Schedule 6 substance, or collect, cultivate or keep any plant or portion thereof from which any such substance can be extracted, derived, produced or manufactured.

(*b*) 'n Bylae 6-stof mag nie verkoop word nie—

(i) deur iemand anders as 'n apteker of 'n kwekeling-apteker handelende onder die persoonlike toesig van 'n apteker, op 'n voorskrif uitgereik deur 'n geneesheer, tandarts of veearts, vir toebereiding aangebied nie later nie as dertig dae vanaf die datum van uitreiking daarvan en wat as die hoeveelheid van sodanige stof wat daarkragtens verkoop moet word, 'n hoeveelheid vermeld wat nie groter is nie as dié wat benodig is vir aaneenlopende gebruik vir 'n tydperk van dertig dae, soos bepaal deur die persoon wat die voorskrif uitgereik het, deur die pasiënt of, in die geval van 'n deur 'n veearts uitgereikte voorskrif, deur die persoon aan wie sodanige stof afgelewer moet word; of

(ii) aan iemand anders as 'n geneesheer, tandarts, veearts of apteker op vertoon van 'n skriftelike bestelling onderteken deur sodanige geneesheer, tandarts, veearts of apteker; en

(iii) tensy die verkoper in 'n voorskrifboek of 'n bestelboek wat op die voorgeskrewe wyse gehou moet word, al die voorgeskrewe besonderhede van bedoelde verkoop op die voorgeskrewe wyse opteken; en

(iv) in die geval van 'n verkoop soos bepaal in subparagraaf (i) of (ii), in 'n groter hoeveelheid as dié vermeld in die voorskrif of bestelling, en nie meer as een uitgifte van daardie stof mag op daardie voorskrif of bestelling verstrek word nie.

(*c*) 'n Verkoper moet, in die geval van 'n verkoop soos bepaal in subparagraaf (i) of (ii) van paragraaf (*b*), die betrokke voorskrif of bestelling behou vir 'n tydperk van minstens drie jaar vanaf die datum van daardie verkoop.

(*d*) Behoudens, *mutatis mutandis*, die voorbehoudsbepaling by subartikel (7) (*c*), mag 'n Bylae 6-stof nie behalwe as geneesmiddel toegedien of gebruik word nie.

(*e*) (i) 'n Bylae 6-stof mag nie vervaardig of by die groot maat verkoop of ingevoer of uitgevoer word nie tensy die vervaardiger, groothandelaar, invoerder of uitvoerder, na gelang van die geval, in 'n boek wat die „Register van Bylae 6-stowwe" heet, die voorgeskrewe besonderhede met betrekking tot bedoelde vervaardiging, verkoop, invoer of uitvoer laat inskrywe.

(ii) Elke sodanige boek moet op die voorgeskrewe wyse gehou word en die balans daarvan moet opgemaak word sodat duidelik blyk hoeveel van elke soort Bylae 6-stof in voorraad oorbly op die laaste dag van Maart, Junie, September en Desember van elke jaar, en die balans moet opgemaak word binne veertien dae na elkeen van voormelde datums.

(*b*) A Schedule 6 substance shall not be sold—

(i) by any person other than a pharmacist or a trainee pharmacist acting under the personal supervision of a pharmacist, upon a prescription issued by a medical practitioner, denist or veterinarian, presented for dispensing not later than thirty days as from the date of issue thereof and setting forth as the quantity of such substance to be sold thereunder, a quantity not greater than that required for continuous use for a period of thirty days, as determined by the person who issued the prescription, by the patient or, in the case of a prescription given by a veterinarian, by the person to whom such substance is to be delivered; or

(ii) to any person other than a medical practitioner, dentist, veterinarian or pharmacist on production of a written order signed by such medical practitioner, dentist, veterinarian or pharmacist; and

(iii) unless the seller enters in the prescribed manner in a prescription book or an order book required to be kept in the prescribed manner, all the prescribed particulars of such sale; and

(iv) in the case of a sale as provided in subparagraph (i) or (ii), in a quantity greater than that stated in the prescription or order, and not more than one issue of such substance shall be made on such prescription or order.

(*c*) Any seller shall, in the case of a sale as provided in subparagraph (i) or (ii) of paragraph (*b*), retain the prescription or order concerned for a period of not less than three years as from the date of such sale.

(*d*) Subject, *mutatis mutandis*, to the proviso to subsection (7) (*c*), a Schedule 6 substance shall not be administered or used for other than medicinal purposes.

(*e*) (i) A Schedule 6 substance shall not be manufactured or sold by wholesale or imported or exported unless the manufacturer, wholesaler, importer or exporter, as the case may be, causes to be entered in a book to be called the 'Schedule 6 Substances Register' the prescribed particulars relating to such manufacture, sale, importation or exportation.

(ii) Every such book shall be kept in the prescribed manner, and shall be balanced so as to show clearly the quantity of every Schedule 6 substance remaining in stock as on the last day of March, June, September and December of each year, the balancing to be completed within the fourteen days following each of the abovementioned dates.

(*f*) Niemand mag 'n Bylae 6-stof vervaardig, invoer of uitvoer nie, tensy—

(i) 'n permit vir bedoelde vervaardiging, invoer of uitvoer aan hom deur die Sekretaris op aanbeveling van die raad en onderworpe aan die voorgeskrewe voorwaardes uitgereik is; of

(ii) 'n permit aan hom deur die Sekretaris op aanbeveling van die raad en onderworpe aan die voorgeskrewe voorwaardes uitgereik is vir die kweek of insamel van plante of deel daarvan waaruit so 'n stof afgetrek, verkry, voortgebring of vervaardig kan word.

(*g*) Die Sekretaris kan, op aanbeveling van die raad en onderworpe aan die voorwaardes en vereistes wat die Sekretaris op daardie aanbeveling bepaal, aan iemand 'n permit uitreik om 'n Bylae 6 stof te verkry, besit of gebruik, of om 'n plant of deel daarvan waaruit so 'n stof afgetrek, verkry, voortgebring of vervaardig kan word, vir wetenskaplike, navorsings- of opvoedkundige doeleindes in te samel, te kweek of aan te hou.

(9) (*a*) Behalwe vir sover deur die bepalings van hierdie subartikel veroorloof, mag niemand 'n Bylae 7 stof gebruik of besit of vervaardig nie, of 'n plant of deel daarvan waaruit so 'n stof afgetrek, verkry, voortgebring of vervaardig kan word, insamel, kweek of aanhou nie.

(*b*) 'n Bylae 7 stof mag nie verkoop word nie—

(i) deur iemand anders as 'n apteker of 'n kwekeling-apteker handelende onder die persoonlike toesig van 'n apteker, op 'n voorskrif uitgereik deur 'n geneesheer, tandarts of veearts, vir toebereiding aangebied nie later nie as dertig dae vanaf die datum van uitreiking daarvan en wat as die hoeveelheid van sodanige stof wat daarkragtens verkoop moet word, 'n hoeveelheid vermeld wat nie groter is nie as dié wat benodig is vir aaneenlopende gebruik vir 'n tydperk van dertig dae, soos bepaal deur die persoon wat die voorskrif uitgereik het, deur die pasiënt of, in die geval van 'n deur 'n veearts uitgereikte voorskrif, deur die persoon aan wie sodanige stof afgelewer moet word; of

(ii) aan iemand anders as 'n geneesheer, tandarts, veearts of apteker op 'n voorgeskrewe skriftelike bestelling op die voorgeskrewe wyse uitgereik;

(iii) tensy die verkoper in 'n boek wat die „Register van Bylae 7-stowwe" heet, die voorgeskrewe besonderhede met betrekking tot bedoelde verkoop laat inskrywe; en

(iv) in die geval van 'n verkoop soos bepaal in subparagraaf (i) of (ii), in 'n groter hoeveelheid as dié vermeld in die voorskrif of bestelling, en nie meer as een uitgifte van daardie stof mag op daardie voorskrif of bestelling verstrek word nie.

(*c*) Behoudens, *mutatis mutandis*, die voorbehoudsbepaling by subartikel (7) (*c*), mag 'n Bylae 7-stof nie behalwe as geneesmiddel toegedien of gebruik word nie.

(*f*) No person shall manufacture, import or export any Schedule 6 substance unless—

(i) a permit for such manufacture, importation or exportation has been issued to him by the Secretary on the recommendation of the council and subject to the prescribed conditions; or

(ii) a permit has been issued to him by the Secretary on the recommendation of the council and subject to the prescribed conditions, for the cultivation or collection of plants, or any portion thereof, from which any such substance can be extracted, derived, produced or manufactured.

(*g*) The Secretary may, on the recommendation of the council, issue, subject to such conditions and requirements as the Secretary may on such recommendation determine, a permit to any person to acquire, possess or use any Schedule 6 substance, or to collect, cultivate or keep, for scientific, research or educational purposes, any plant or any portion thereof from which any such substance can be extracted, derived, produced or manufactured.

(9) (*a*) Save as is permitted by the provisions of this subsection, no person shall use or have in his possession or manufacture any Schedule 7 substance, or collect, cultivate or keep any plant or portion thereof from which any such substance can be extracted, derived, produced or manufactured.

(*b*) A Schedule 7 substance shall not be sold—

(i) by any person other than a pharmacist or a trainee pharmacist acting under the personal supervision of a pharmacist, upon a prescription issued by a medical practitioner, dentist or veterinarian, presented for dispensing not later than thirty days as from the date of issue thereof and setting forth as the quantity of such substance to be sold thereunder, a quantity not greater than that required for continuous use for a period of thirty days, as determined by the person who issued the prescription, by the patient or, in the case of a prescription given by a veterinarian, by the person to whom such substance is to be delivered; or

(ii) to any person other than a medical practitioner, dentist, veterinarian or pharmacist on a prescribed written order issued in the prescribed manner; and

(iii) unless the seller causes to be entered in a book to be called the 'Schedule 7 Substances Register' the prescribed particulars relating to such sale; and

(iv) in the case of a sale as provided in subparagraph (i) or (ii), in a quantity greater than that stated in the prescription or order, and not more than one issue of such substance shall be made on such prescription or order.

(*c*) Subject, *mutatis mutandis*, to the proviso to subsection (7) (*c*), a Schedule 7 substance shall not be administered or used for other than medicinal purposes.

(*d*) 'n Bylae 7-stof mag nie vervaardig of by die groot maat verkoop of ingevoer of uitgevoer word nie tensy die vervaardiger, groothandelaar, invoerder of uitvoerder, na gelang van die geval, in die in paragraaf (*b*) (iii) bedoelde Register van Bylae 7-stowwe die voorgeskrewe besonderhede met betrekking tot bedoelde vervaardiging, verkoop, invoer of uitvoer laat inskrywe.

(*e*) Genoemde Register van Bylae 7-stowwe moet op die voorgeskrewe wyse gehou word en die balans daarvan moet opgemaak word sodat duidelik blyk hoeveel van elke soort Bylae 7-stof in voorraad oorbly op die laaste dag van Maart, Junie, September en Desember van elke jaar, en die balans moet opgemaak word binne veertien dae na elkeen van voormelde datums.

(*f*) Niemand mag 'n Bylae 7-stof vervaardig, invoer of uitvoer nie, tensy—

(i) 'n permit vir bedoelde vervaardiging, invoer of uitvoer aan hom deur die Sekretaris op aanbeveling van die raad en onderworpe aan die voorgeskrewe voorwaardes uitgereik is; of

(ii) 'n permit aan hom deur die Sekretaris op aanbeveling van die raad en onderworpe aan die voorgeskrewe voorwaardes uitgereik is vir die kweek of insamel van plante of deel daarvan waaruit so 'n stof afgetrek, verkry, voortgebring of vervaardig kan word.

(*g*) Die Sekretaris kan, op aanbeveling van die raad en onderworpe aan die voorwaardes en vereistes wat die Sekretaris op daardie aanbeveling bepaal, aan iemand 'n permit uitreik om 'n Bylae 7-stof in die permit vermeld, te verkry, besit of gebruik, of om 'n plant of deel daarvan waaruit so 'n stof afgetrek, verkry, voortgebring of vervaardig kan word, vir bepaalde wetenskaplike, navorsings-, analitiese of opvoedkundige doeleindes in te samel, te kweek of aan te hou.

(10) Niemand mag—

(*a*) 'n Bylae 8-stof verkry, gebruik, besit, vervaardig of invoer nie behalwe vir analitiese of navorsingsdoeleindes en tensy 'n permit vir bedoelde verkryging, gebruik, besit, vervaardiging of invoer aan hom deur die Sekretaris op aanbeveling van die raad uitgereik is; of

(*b*) 'n plant of deel daarvan waaruit so 'n stof afgetrek, verkry, voortgebring of vervaardig kan word, verkry, invoer, insamel, kweek, aanhou of uitvoer nie, tensy 'n permit om sodanige plant of 'n deel daarvan te verkry, in te voer, in te samel, te kweek, aan te hou of uit te voer aan hom deur die Sekretaris op aanbeveling van die raad uitgereik is.

(11) 'n Bylae 9-stof mag nie verkry word nie deur iemand anders as die Sekretaris, ten einde dit aan 'n geneesheer op die voorgeskrewe voorwaardes te verskaf vir die behandeling, onderworpe aan die voorwaardes wat die Sekretaris op aanbveling van die raad bepaal, van 'n bepaalde pasiënt van daardie geneesheer.

(12) Ondanks die ander bepalings van hierdie artikel, kan die Sekretaris na oorlegpleging met die

(*d*) A Schedule 7 substance shall not be manufactured or sold by wholesale or imported or exported unless the manufacturer, wholesaler, importer or exporter, as the case may be, causes to be entered in the Schedule 7 Substances Register referred to in paragraph (*b*) (iii), the prescribed particulars relating to such manufacture, sale, importation or exportation.

(*e*) The said Schedule 7 Substances Register shall be kept in the prescribed manner, and shall be balanced so as to show clearly the quantity of every Schedule 7 substance remaining in stock as on the last day of March, June, September and December of each year, the balancing to be completed within the fourteen days following each of the abovementioned dates.

(*f*) No person shall manufacture, import or export any Schedule 7 substance unless—

(i) a permit for such manufacture, importation or exportation has been issued to him by the Secretary on the recommendation of the council and subject to the prescribed conditions; or

(ii) a permit has been issued to him by the Secretary on the recommendation of the council and subject to the prescribed conditions, for the cultivation or collection of plants, or any portion thereof, from which any such substance can be extracted, derived, produced or manufactured.

(*g*) The Secretary may, on the recommendation of the council, issue, subject to such conditions and requirements as the Secretary may on such recommendation determine, a permit to any person to acquire, possess or use any Schedule 7 substance specified in such permit or to collect, cultivate or keep, for specified scientific, research, analytical or educational purposes, any plant or any portion thereof from which any such substance can be extracted, derived, produced or manufactured.

(10) No person shall—

(*a*) acquire, use, have in his possession, manufacture or import any Schedule 8 substance except for analytical or research purposes and unless a permit for such acquisition, use, possession, manufacture or importation has been issued to him by the Secretary on the recommendation of the council; or

(*b*) acquire, import, collect, cultivate, keep or export any plant or any portion thereof from which any such substance can be extracted, derived, produced or manufactured, unless a permit to acquire, import, collect, cultivate, keep or export such plant or any portion thereof, has been issued to him by the Secretary on the recommendation of the council.

(11) A Schedule 9 substance shall not be acquired by any person other than the Secretary for the purpose of providing a medical practitioner therewith, on the prescribed conditions, for the treatment of a particular patient of that medical practitioner subject to such conditions as the Secretary, on the recommendation of the council, may determine.

(12) Notwithstanding the other provisions of this section, the Secretary may, after consultation

Aptekersraad, 'n permit aan 'n persoon of organisasie wat 'n gesondheidsdiens verrig, uitreik wat sodanige persoon of organisasie magtig om 'n bepaalde Bylae 1-, Bylae 2-, Bylae 3- of Bylae 4-stof te verkry, besit, gebruik of voorsien, en sodanige permit is onderworpe aan die voorwaardes wat die Sekretaris bepaal.

(13) Ondanks die ander bepalings van hierdie artikel kan die Minister op aanbeveling van die raad en na oorlegpleging met die Aptekersraad, 'n permit uitreik aan 'n persoon wat nie as 'n apteker geregistreer is nie, om enige medisyne of gelyste stof wat in die permit aangedui word, te vervaardig of verpak en verkoop, en bedoelde persoon kan dan sodanige medisyne of stof op die plek, op die wyse en op die voorwaardes in die permit vermeld, vervaardig of verpak en verkoop.

(14) Ondanks die ander bepalings van hierdie artikel, kan 'n apteker 'n groter of kleiner hoeveelheid van 'n Bylae 1-, Bylae 2-, Bylae 3- of Bylae 4-stof verkoop as die hoeveelheid wat voorgeskryf of bestel is, en wel volgens die terapeutiese verpakking in die oorspronklike houer van sodanige stof soos aan hom gelewer: Met dien verstande dat die hoeveelheid wat aldus verkoop word, nie groter of kleiner mag wees nie as vyf-en-twintig persent van die hoeveelheid wat in die betrokke voorskrif of bestelling aangedui word.

(15) Die bepalings van hierdie artikel word nie uitgelê nie asof dit—

(*a*) 'n geneesheer, tandarts of veearts verbied om 'n Bylae 1-, Bylae 2-, Bylae 3-, Bylae 4-, Bylae 5-, Bylae 6- of Bylae 7-stof in die loop van die wettige verrigting van sy professionele bedrywighede as sodanig te verkoop aan of vir 'n pasiënt of dier onder sy sorg of behandeling;

(*b*) iemand wat by 'n vervaardiger van of groothandelaar in farmaseutiese produkte in diens is en deur sodanige vervaardiger of handelaar skriftelik daartoe gemagtig is, verbied om 'n Bylae 1-, Bylae 2-, Bylae 3- of Bylae 4-stof aan 'n geneesheer, tandarts, apteker of veearts op die voorgeskrewe voorwaardes te verkoop.".

Wysiging van artikel 23 in Engelse teks van Wet 101 van 1965.

**22.** Artikel 23 van die Hoofwet word hierby gewysig deur in die Engelse teks die woord „drug", waar dit ook al voorkom, deur die woord „medicine" te vervang.

Wysiging van artikel 24 van Wet 101 van 1965.

**23.** Artikel 24 van die Hoofwet word hierby gewysig deur subartikel (1) deur die volgende subartikel te vervang:

„(1) Iemand wat hom veronreg ag deur 'n beslissing van die raad (behalwe enige beslissing hoegenaamd beoog in artikel 22A) kan teen daardie beslissing by die appèlraad appèl aanteken.".

Vervanging van artikel 26 van Wet 101 van 1965.

**24.** (1) Artikel 26 van die Hoofwet word hierby deur die volgende artikel vervang:

„Inspekteurs.

**26.** (1) Die Sekretaris kan, na oorlegpleging met die raad, die persone as inspekteurs magtig wat hy vir die behoorlike uitvoering van hierdie Wet nodig ag.

(2) Elke inspekteur moet van 'n deur die registrateur ondertekende sertifikaat voorsien word waarin verklaar word dat hy kragtens hierdie Wet as 'n inspekteur gemagtig is.

with the Pharmacy Board, issue a permit to any person or organization performing a health service, authorizing such person or organization to acquire, possess, use or supply any specified Schedule 1, Schedule 2, Schedule 3 or Schedule 4 substance, and such permit shall be subject to such conditions as the Secretary may determine.

(13) Notwithstanding the other provisions of this section, the Minister may, on the recommendation of the council and after consultation with the Pharmacy Board, issue a permit to any person who is not registered as a pharmacist, to manufacture or pack and sell any medicine or Scheduled substance specified in the permit, and thereupon such person may, at the place, in the manner and on the conditions specified in the permit, manufacture or pack and sell such medicine or substance.

(14) Notwithstanding the other provisions of this section, a pharmacist may sell a greater or a lesser quantity of a Schedule 1, Schedule 2, Schedule 3 or Schedule 4 substance than the quantity prescribed or ordered, according to the therapeutic pack in the original container of such substance as supplied to him: Provided that the quantity so sold shall not exceed or be less than, twenty-five per cent of the quantity specified in the prescription or order in question.

(15) Nothing in this section contained shall be construed as prohibiting—

(*a*) any medical practitioner, dentist or veterinarian from selling any Schedule 1, Schedule 2, Schedule 3, Schedule 4, Schedule 5, Schedule 6 or Schedule 7 substance in the course of lawfully carrying on his professional activities as such to or for any patient or animal under his care or treatment;

(*b*) any person employed by a manufacturer of or wholesale dealer in pharmaceutical products, and authorized thereto in writing by such manufacturer or dealer, from selling any Schedule 1, Schedule 2, Schedule 3 or Schedule 4 substance to any medical practitioner, dentist, pharmacist or veterinarian on the prescribed conditions.".

Amendment of section 23 of Act 101 of 1965.

**22.** Section 23 of the principal Act is hereby amended by the substitution for the word "drug" wherever it occurs of the word "medicine".

Amendment of section 24 of Act 101 of 1965.

**23.** Section 24 of the principal Act is hereby amended by the substitution for subsection (1) of the following subsection:

"(1) Any person who is aggrieved by any decision of the council (not being any decision whatsoever contemplated in section 22A) may appeal against such decision to the appeal board.".

Substitution of section 26 of Act 101 of 1965.

**24.** (1) The following section is hereby substituted for section 26 of the principal Act:

"Inspectors.

**26.** (1) The Secretary may, after consultation with the council, authorize such persons as inspectors, as he may consider necessary for the proper enforcement of this Act.

(2) Every inspector shall be furnished with a certificate signed by the registrar and stating that he has been authorized as an inspector under this Act.

(3) Voordat 'n inspekteur enige bevoegdheid of werksaamheid kragtens hierdie Wet uitoefen of verrig, moet hy aan enigiemand wat daardeur geraak word, die in subartikel (2) bedoelde sertifikaat voorlê en vertoon.".

(2) Iemand wat voor die inwerkingtreding van subartikel (1) van hierdie artikel kragtens artikel 26 (1) van die Hoofwet as inspekteur aangestel is en wie se aanstelling as sodanig onmiddellik voor daardie inwerkingtreding van krag was, word geag kragtens artikel 26 (1) van die Hoofwet, soos deur subartikel (1) van hierdie artikel vervang, as inspekteur gemagtig te wees.

Vervanging van artikel 27 van Wet 101 van 1965.

**25.** (1) Artikel 27 van die Hoofwet word hierby deur die volgende artikel vervang:

„Ontleders, farmakoloë en patoloë.

**27.** Die Sekretaris kan na oorlegpleging met die raad die magtiging aan die ontleders, farmakoloë en patoloë verleen wat hy vir die behoorlike uitvoering van hierdie Wet nodig ag.".

(2) 'n Ontleder, farmakoloog of patoloog wat voor die inwerkingtreding van subartikel (1) van hierdie artikel kragtens artikel 27 (1) van die Hoofwet aangestel is en wie se bedoelde aanstelling onmiddellik voor daardie inwerkingtreding van krag was, word geag kragtens artikel 27 van die Hoofwet, soos deur subartikel (1) van hierdie artikel vervang, magtiging verleen te wees.

Wysiging van artikel 28 van Wet 101 van 1965.

**26.** Artikel 28 van die Hoofwet word hierby gewysig—

(*a*) deur in subartikels (1) en (2) die woord „medisyne", orals waar dit voorkom, deur die woorde „medisyne of gelyste stof" te vervang; en

(*b*) deur subartikel (4) deur die volgende subartikel te vervang:

„(4) Die eienaar van die medisyne of gelyste stof waarvan die monster geneem is, kan 'n bedrag gelykstaande met die markwaarde daarvan van die Sekretaris eis.".

Wysiging van artikel 29 van Wet 101 van 1965.

**27.** Artikel 29 van die Hoofwet word hierby gewysig—

(*a*) deur paragraaf (*h*) deur die volgende paragraaf te vervang:

„(*h*) in verband met 'n medisyne of gelyste stof 'n valse of misleidende verklaring maak—

(i) in 'n aansoek om die registrasie daarvan; of

(ii) by die verkoop daarvan; of";

(*b*) deur paragraaf (*i*) deur die volgende paragraaf te vervang:

„(*i*) 'n medisyne of gelyste stof, op die houer waarvan 'n valse of misleidende verklaring in verband met die inhoud geskryf is, verkoop; of";

(*c*) deur aan die einde van paragraaf (*j*) die woord „of' by te voeg; en

(*d*) deur die volgende paragraaf by te voeg:

„(*k*) 'n bepaling van artikel 22A oortree of versuim om te voldoen aan 'n voorwaarde daarkragtens opgelê of so 'n voorwaarde oortree,".

Wysiging van artikel 30 van Wet 101 van 1965.

**28.** Artikel 30 van die Hoofwet word hierby gewysig—

(*a*) deur in subartikel (2) die woord „medisyne" deur die woorde „medisyne of gelyste stof" te vervang; en

(*b*) deur subartikel (3) deur die volgende subartikel te vervang:

(3) An inspector shall, before he exercises or performs any power or function under this Act, produce and exhibit to any person affected thereby, the certificate referred to in subsection (2).".

(2) Any person appointed, prior to the commencement of subsection (1) of this section, as an inspector under section 26 (1) of the principal Act, whose appointment as such was in force immediately prior to such commencement, shall be deemed to have been authorized as an inspector under section 26 (1) of the principal Act as substituted by subsection (1) of this section.

Substitution of section 27 of Act 101 of 1965.

**25.** (1) The following section is hereby substituted for section 27 of the principal Act:

"Analysts, pharmacologists and pathologists.

**27.** The Secretary may, after consultation with the council, grant such authority to such analysts, pharmacologists and pathologists as he may consider necessary for the proper enforcement of this Act.".

(2) Any analyst, pharmacologist or pathologist appointed, prior to the commencement of subsection (1) of this section, under section 27 (1) of the principal Act, whose relevant appointment was in force immediately prior to such commencement, shall be deemed to have been granted authority under section 27 of the principal Act as substituted by subsection (1) of this section.

Amendment of section 28 of Act 101 of 1965.

**26.** Section 28 of the principal Act is hereby amended—

(*a*) by the substitution in subsections (1) and (2) for the word "drug", wherever it occurs, of the words "medicine or Scheduled substance"; and

(*b*) by the substitution for subsection (4) of the following subsection:

"(4) The owner of the medicine or Scheduled substance from which the sample was taken may claim from the Secretary an amount equal to the market value thereof.".

Amendment of section 29 of Act 101 of 1965.

**27.** Section 29 of the principal Act is hereby amended—

(*a*) by the substitution for paragraph (*h*) of the following paragraph:

"(*h*) makes any false or misleading statement in connection with any medicine or Scheduled substance—

(i) in an application for the registration thereof; or

(ii) in the course of the sale thereof; or";

(*b*) by the substitution for paragraph (*i*) of the following paragraph:

"(*i*) sells any medicine or Scheduled substance upon the container of which a false or misleading statement in connection with the contents is written; or";

(*c*) by the addition of the word "or" at the end of paragraph (*j*); and

(*d*) by the addition of the following paragraph:

"(*k*) contravenes any provision of section 22A or contravenes or fails to comply with any condition imposed thereunder,".

Amendment of section 30 of Act 101 of 1965.

**28.** Section 30 of the principal Act is hereby amended—

(*a*) by the substitution in subsection (2) for the word "drug" of the word "medicine or Scheduled substance"; and

(*b*) by the substitution for subsection (3) of the following subsection:

„(3) 'n Kragtens hierdie Wet verbeurdverklaarde medisyne of gelyste stof word vernietig of andersins mee gehandel soos die Sekretaris gelas.".

Wysiging van artikel 31 van Wet 101 van 1965.

**29.** Artikel 31 van die Hoofwet word hierby gewysig deur in paragrawe (*a*) en (*d*) van subartikel (1) die woord „medisyne" deur die woorde „medisyne of gelyste stof" te vervang.

Wysiging van artikel 32 in Engelse teks van Wet 101 van 1965.

**30.** Artikel 32 van die Hoofwet word hierby gewysig deur in die Engelse teks die woord „drug", waar dit ook al voorkom, deur die woord „medicine" te vervang.

Vervanging van artikel 35 van Wet 101 van 1965, soos gewysig deur artikel 5 van Wet 29 van 1968, artikel 1 van Wet 88 van 1970 en artikel 7 van Wet 95 van 1971.

**31.** (1) Artikel 35 van die Hoofwet word hierby deur die volgende artikel vervang:

„Regulasies.

**35.** (1) Die Minister kan, op aanbeveling van die raad, regulasies uitvaardig—

(i) wat die kategorieë persone voorskryf deur wie aansoek om die registrasie van 'n medisyne gedoen kan word;

(ii) wat die vorms wat by 'n aansoek om die registrasie van 'n medisyne gebruik moet word en die besonderhede wat saam met so 'n aansoek verstrek moet word (met inbegrip van besonderhede betreffende die metode waarvolgens die betrokke medisyne of 'n bestanddeel van daardie medisyne vervaardig word en die perseel waarop dit vervaardig word), voorskryf;

(iii) wat voorsiening maak vir die indeling van medisyne in klasse of kategorieë vir die doeleindes van hierdie Wet;

(iv) wat die monsters van enige medisyne en die hoeveelheid daarvan wat 'n aansoek om die registrasie van 'n medisyne moet vergesel, voorskryf;

(v) wat die vorm waarin die medisyne-register gehou moet word en die besonderhede wat ten opsigte van enige geregistreerde medisyne daarin aangeteken moet word, voorskryf;

(vi) wat die vorm van 'n registrasiesertifikaat van medisyne voorskryf;

(vii) wat die wyse waarop 'n pakket wat medisyne of 'n gelyste stof bevat, geëtiketteer, gepak of verseël moet word, voorskryf;

(viii) wat die besonderhede met betrekking tot die gebruik daarvan wat tesame met 'n medisyne of gelyste stof wat verkoop word, verstrek moet word en die wyse waarop sodanige besonderhede verstrek moet word, voorskryf;

(ix) wat die besonderhede wat in 'n advertensie betreffende 'n medisyne of gelyste stof moet verskyn, voorskryf, of wat die insluiting van bepaalde besonderhede in so 'n advertensie of die verspreiding van 'n advertensie betreffende 'n medisyne of gelyste stof aan 'n bepaalde persoon of 'n bepaalde klas of kategorie van persone of aan 'n bepaalde organisasie of 'n bepaalde klas of kategorie van organisasies verbied;

(x) wat die vereistes met betrekking tot die samestelling, terapeutiese bruikbaarheid en effek, suiwerheid of enige ander eienskap waaraan 'n medisyne of bestanddeel daarvan moet voldoen, voorskryf;

(xi) waarby die besonderhede voorgeskryf word wat in die *Staatskoerant* afgekondig moet word ten

"(3) Any medicine or Scheduled substance forfeited under this Act shall be destroyed or otherwise dealt with as the Secretary may direct.".

Amendment of section 31 of Act 101 of 1965.

**29.** Section 31 of the principal Act is hereby amended by the substitution in paragraphs (*a*) and (*d*) of subsection (1) for the word "drug" of the words "medicine or Scheduled substance".

Amendment of section 32 of Act 101 of 1965.

**30.** Section 32 of the principal Act is hereby amended by the substitution for the word "drug", wherever it occurs, of the word "medicine".

Substitution of section 35 of Act 101 of 1965, as amended by section 5 of Act 29 of 1968, section 1 of Act 88 of 1970 and section 7 of Act 95 of 1971.

**31.** (1) The following section is hereby substituted for section 35 of the principal Act:

"Regulations. **35.** (1) The Minister may, on the recommendation of the council, make regulations—

(i) prescribing the categories of persons by whom application may be made for the registration of any medicine;

(ii) prescribing the forms which shall be used for any application for the registration of any medicine and the particulars which shall be furnished with any such application (including particulars regarding the method by which the medicine in question or any component of such medicine is manufactured and the premises in which such medicine or any such component is manufactured);

(iii) providing for the classification of medicines into classes or categories for the purposes of this Act;

(iv) prescribing the samples of any medicine and the quantity thereof which shall accompany any application for the registration of a medicine;

(v) prescribing the form in which the medicines register shall be kept and the particulars which shall be entered therein in respect of any registered medicine;

(vi) prescribing the form of any certificate of registration of any medicine;

(vii) prescribing the manner in which any package containing any medicine or Scheduled substance shall be labelled, packed or sealed;

(viii) prescribing the particulars in regard to the use thereof which shall be furnished with any medicine or Scheduled substance sold, and the manner in which such particulars shall be furnished;

(ix) prescribing the particulars which shall appear in any advertisement relating to any medicine or Scheduled substance or prohibiting the inclusion of any specified particulars in any advertisement relating to any medicine or Scheduled substance, or the distribution of any such advertisement to a specified person or a specified class or category of persons or to a specified organization or a specified class or category of organizations;

(x) prescribing the requirements with which any medicine or any component thereof shall comply in regard to composition, therapeutic suitability and effect, purity or any other property;

(xi) prescribing the particulars which shall be published in the *Gazette* in respect of any

opsigte van 'n aansoek om registrasie in subartikel (11) van artikel 15 bedoel;

(xii) wat die prosedure by vergaderings van die raad en van die appèlraad en van enige kragtens artikel 9 aangestelde komitee (met inbegrip van die kworum in die geval van komitees) en die wyse waarop vergaderings van die appèlraad en van enige sodanige komitee belê moet word, voorskryf;

(xiii) waarby voorgeskryf word die voorwaardes waarop 'n in artikel 22A (1) bedoelde lisensie uitgereik kan word, die vorms wat vir 'n aansoek om so 'n lisensie gebruik moet word, die besonderhede wat tesame met so 'n aansoek verstrek moet word, die medisyne of gelyste stof wat kragtens so 'n lisensie verkoop kan word en die opgawes en verslae wat deur die lisensie-owerheid aan die raad verstrek moet word;

(xiv) waarby voorgeskryf word die besonderhede wat op 'n voorskrif of 'n bestelling vir 'n medisyne of 'n gelyste stof moet verskyn, die getal uitgiftes van 'n medisyne of 'n gelyste stof wat kragtens so 'n bepaalde voorskrif of bestelling verstrek kan word, die wyse waarop so 'n voorskrif of bestelling uitgereik moet word en die tydperk waarvoor so 'n voorskrif of bestelling behou moet word;

(xv) wat die voorwaardes waarop 'n in artikel 22A (15) (*b*) bedoelde persoon die in daardie artikel bedoelde gelyste stowwe kan aanhou en verkoop, voorskryf;

(xvi) wat die voorwaardes waarop sekere bepaalde Bylae 1-stowwe deur iemand anders as 'n geneesheer, tandarts, veearts of apteker kragtens 'n in artikel 22A (1) bedoelde lisensie verkoop kan word, voorskryf;

(xvii) waarby voorgeskryf word die vorms van lisensies, registers, voorskrifboeke, aantekenings en ander dokumente wat ten opsigte van gelyste stowwe gehou of gebruik moet word, die wyse waarop hulle gehou moet word, die besonderhede wat daarin aangeteken moet word en die plek waar en die tydperk waarvoor hulle behou moet word;

(xviii) waarby vereis word die verstrekking van opgawes en verslae en inligting ten opsigte van Bylae 6- en Bylae 7-stowwe en Bepaalde Bylae 5-stowwe, en plante waaruit enige sodanige stof afgetrek, verkry, voortgebring of vervaardig kan word, en ten opsigte van enige medisyne of ander stof waarvan enige sodanige gelyste stof 'n bestanddeel is;

(xix) aangaande die oorlaai of die uitvoer uit die Republiek of die gebied of die invoer daarheen van enige Bylae 5-, Bylae 6-, Bylae 7-, Bylae 8- of Bylae 9-stof, met aangifte van die hawens of plekke waar sodanige stof in die Republiek of die gebied ingebring kan word;

(xx) tot magtiging en reëling of beperking van die vervoer van sodanige stowwe deur die Republiek en die gebied;

(xxi) waarby voorgeskryf word die wyse waarop pakkette wat Bylae 5-, Bylae 6-, Bylae 7- of Bylae 8-stowwe bevat, hy invoer in die Republiek of die gebied of vervaardiging in die Republiek of

application for registration referred to in subsection (11) of section 15;

(xii) prescribing the procedure at meetings of the council and of the appeal board and of any committee appointed under section 9 (including the quorum in the case of committees) and the manner in which meetings of the appeal board and of any such committee shall be called;

(xiii) prescribing the conditions on which any licence referred to in section 22A (1) may be issued, the forms which shall be used for an application for any such licence, the particulars which shall be furnished with any such application, the medicine or Scheduled substance which may be sold under any such licence and the returns and reports which shall be furnished to the council by the licensing authority;

(xiv) prescribing the particulars which shall appear on a prescription or an order for a medicine or a Scheduled substance, the number of issues of a medicine or a Scheduled substance that may be made on any such specified prescription or order, the manner in which any such prescription or order shall be issued and the period for which any such prescription or order shall be retained;

(xv) prescribing the conditions on which a person referred to in section 22A (15) (*b*) may carry and sell such Scheduled substances as are referred to in that section;

(xvi) prescribing the conditions on which certain specified Schedule 1 substances may be sold by a person other than a medical practitioner, dentist, veterinarian or pharmacist, under a licence referred to in section 22A (1);

(xvii) prescribing the forms of licences, registers, prescription books, records and other documents which shall be kept or used in respect of Scheduled substances, the manner in which they shall be kept, the particulars which shall be entered therein and the place where and the period for which they shall be retained;

(xviii) requiring the furnishing of returns and reports and information in respect of Schedule 6 and Schedule 7 substances and specified Schedule 5 substances, and plants from which any such substance can be extracted, derived, produced or manufactured, and in respect of any medicine or other substance of which any such Scheduled substance is a component;

(xix) as to the transhipment or the exportation from or importation to the Republic or the territory of any Schedule 5, Schedule 6, Schedule 7, Schedule 8 or Schedule 9 substance, and specifying the ports or places at which such substance may be brought into the Republic or the territory;

(xx) authorizing and regulating or restricting the transmission through the Republic and the territory of such substances;

(xxi) prescribing the manner in which packages containing Schedule 5, Schedule 6, Schedule 7 or Schedule 8 substances shall be labelled when

die gebied geëtiketteer moet word en die persone deur wie en die wyse waarop hulle gehou moet word;

(xxii) tot magtiging en reëling van die koop, verkryging, aanhou of gebruik van kokaïenpreparate deur bestuurders of hoofde van fabrieke of werkplase in verband met die behandeling van oogbeserings of vir ander noodsaaklike doeleindes;

(xxiii) tot magtiging en reëling van die koop, verkryging, aanhou of gebruik van gelyste stowwe deur gesagvoerders van skepe of deur die bevelvoerende offisier van 'n vliegtuig;

(xxiv) tot magtiging en reëling van die koop, verkryging, aanhou, toediening of gebruik van gelyste stowwe deur persone wat ingevolge die Wet op Verpleging, 1957 (Wet No. 69 van 1957), as verpleegsters, vroedvroue of verpleegassistente geregistreer of ingeskrywe is;

(xxv) tot magtiging en reëling van die besit, deur persone wat die Republiek of die gebied binnekom of verlaat, van bepaalde hoeveelhede van Bylae 5-, Bylae 6-, Bylae 7- en Bylae 9-stowwe vir persoonlike medisinale gebruik;

(xxvi) aangaande die summiere beslaglegging op en beskikking oor enige gelyste stof wat in die besit of bewaring gevind word van iemand wat nie kragtens hierdie Wet geregtig is om dit aan te hou of te gebruik nie;

(xxvii) aangaande die invoer, vervoer, aanhouding, opslag en verpakking van medisyne en gelyste stowwe, en die wyse waarop medisyne en gelyste stowwe in hospitale aangehou en beheer moet word;

(xxviii) wat die metodes waarvolgens monsters kragtens hierdie Wet geneem kan word en die vorm van die sertifikate wat deur inspekteurs ten opsigte van sodanige monsters uitgereik moet word, voorskryf;

(xxix) wat die metodes wat gevolg moet word en die vorm van die sertifikate wat uitgereik moet word in verband met die toets, ondersoek of ontleding van monsters wat kragtens hierdie Wet geneem word, voorskryf;

(xxx) wat die gelde (ten bedrae van hoogstens honderd rand) wat aan die registrateur betaal moet word ten opsigte van die registrasie van 'n medisyne, die gelde (ten bedrae van hoogstens dertig rand) wat jaarliks aan die registrateur betaal moet word ten opsigte van die behoud van die registrasie van 'n medisyne en die datum waarop laasgenoemde gelde aldus betaal moet word, voorskryf;

(xxxi) met betrekking tot 'n aangeleentheid wat ingevolge hierdie Wet by regulasie voorgeskryf kan word; en

(xxxii) oor die algemeen vir die doeltreffende uitvoering van die oogmerke en doeleindes van hierdie Wet, en die algemeenheid van hierdie bepaling word nie deur die voorafgaande paragrawe van hierdie subartikel beperk nie.

(2) Die Minister moet minstens drie maande voordat hy enige regulasie kragtens subartikel (1) uitvaardig, die teks van daardie regulasie in die *Staatskoerant* laat publiseer tesame met 'n kennisgewing waarby verklaar word dat hy voornemens is om daardie regulasie uit te vaardig en belanghebbende

imported into or manufactured in the Republic or the territory and the persons by whom and the manner in which they shall be kept;

(xxii) authorizing and regulating the purchase, acquisition, keeping or use of preparations of cocaine by managers or persons in charge of factories or workshops in connection with the treatment of eye injuries or for other essential purposes;

(xxiii) authorizing and regulating the purchase, acquisition, keeping or use of Scheduled substances by the masters of ships or by the officer in charge of any aircraft;

(xxiv) authorizing and regulating the purchase, acquisition, keeping, administration or use of Scheduled substances by persons registered or enrolled as nurses, midwives or nursing assistants in terms of the Nursing Act, 1957 (Act No. 69 of 1957);

(xxv) authorizing and regulating the possession by persons entering or departing from the Republic or the territory of specified quantities of Schedule 5, Schedule 6, Schedule 7 and Schedule 9 substances for personal medicinal use;

(xxvi) as to the summary seizure and disposal of any Scheduled substance found in the possession or custody of any person not entitled under this Act to keep or use it;

(xxvii) as to the importation, conveyance, keeping, storage and packing of medicines and Scheduled substances, and the manner in which medicines and Scheduled substances shall be kept and controlled in hospitals;

(xxviii) prescribing the methods in accordance with which samples may be taken under this Act and the form of the certificates to be issued by inspectors in respect of such samples;

(xxix) prescribing the methods to be employed and the form of the certificates to be issued in connection with the testing, examination or analysis of samples taken under this Act;

(xxx) prescribing the fee (not exceeding one hundred rand) to be paid to the registrar in respect of the registration of a medicine, the fee (not exceeding thirty rand) to be paid annually to the registrar in respect of the retention of the registration of a medicine and the date on which the last-mentioned fee shall be so paid;

(xxxi) with regard to any matter which in terms of this Act may be prescribed by regulation; and

(xxxii) generally for the efficient carrying out of the objects and purposes of this Act, and the generality of this provision shall not be limited by the preceding paragraphs of this subsection.

(2) The Minister shall, not less than three months before any regulation is made under subsection (1), cause the text of such regulation to be published in the *Gazette* together with a notice declaring his intention to make that regulation and inviting interested persons to furnish him with any comments

persone uitgenooi word om enige opmerkings daaroor of enige vertoë wat hulle in verband daarmee wil rig, aan hom te verstrek.

(3) Die bepalings van subartikel (2) is nie van toepassing nie ten opsigte van—

(*a*) enige regulasie wat, nadat aan die bepalings van daardie subartikel voldoen is, deur die Minister gewysig is as gevolg van opmerkings of vertoë deur hom ontvang na aanleiding van die kennisgewing ingevolge daardie subartikel uitgereik; of

(*b*) enige regulasie ten opsigte waarvan die Minister, na oorlegpleging met die raad, van oordeel is dat die uitvaardiging daarvan sonder versuim in die openbare belang nodig is.

(4) Geen regulasie word kragtens paragraaf (xxx) van subartikel (1) uitgevaardig nie behalwe in oorleg met die Minister van Finansies.

(5) Regulasies wat kragtens subartikel (1) (x) uitgevaardig word, kan voorskryf dat 'n medisyne of bestanddeel daarvan moet voldoen aan die vereistes wat uiteengesit word in 'n publikasie wat na die mening van die raad algemeen as gesaghebbend erken word.

(6) Regulasies kan kragtens hierdie artikel uitgevaardig word ten opsigte van bepaalde medisyne of gelyste stowwe of klasse of kategorieë van medisyne of gelyste stowwe of ten opsigte van ander medisyne of gelyste stowwe as bepaalde klasse of kategorieë van medisyne of gelyste stowwe, en verskillende regulasies kan aldus ten opsigte van verskillende medisyne of gelyste stowwe of verskillende klasse of kategorieë van medisyne of gelyste stowwe uitgevaardig word.

(7) Regulasies wat kragtens hierdie artikel uitgevaardig word, kan vir oortreding daarvan of versuim om daaraan te voldoen, strawwe voorskryf wat nie 'n boete van vyfhonderd rand of gevangenisstraf vir 'n tydperk van ses maande te bowe gaan nie.".

(2) 'n Regulasie wat kragtens artikel 35 van die Hoofwet van krag was onmiddellik voor die inwerkingtreding van subartikel (1), bly van krag totdat dit kragtens gemelde artikel 35 gewysig of ingetrek word.

Wysiging van artikel 36 in Engelse teks van Wet 101 van 1965.

**32.** Artikel 36 van die Hoofwet word hierby gewysig deur in die Engelse teks die woord „drug" deur die woord „medicine" te vervang.

Vervanging van artikel 37 van Wet 101 van 1965.

**33.** Artikel 37 van die Hoofwet word hierby deur die volgende artikel vervang:

„Medisyne vir uitvoer vervaardig.

**37.** Ondanks andersluidende bepalings van hierdie Wet, is die bepalings van hierdie Wet met betrekking tot die registrasie van medisyne nie van toepassing nie ten opsigte van enige medisyne of enige hoeveelheid van enige medisyne wat in die Republiek of die gebied vervaardig of ingevoer word uitsluitlik met die doel om dit uit die Republiek of die gebied uit te voer en wat nie in die Republiek of die gebied gebruik of van die hand gesit word om daarin gebruik te word nie, en ten opsigte waarvan die raad 'n sertifikaat verleen het dat hy aangaande die kwaliteit, suiwerheid en veiligheid van die medisyne oortuig is.".

thereon or any representations they may wish to make in regard thereto.

(3) The provisions of subsection (2) shall not apply in respect of—

(*a*) any regulation which, after the provisions of that subsection have been complied with, has been amended by the Minister in consequence of comments or representations received by him in pursuance of the notice issued thereunder; or

(*b*) any regulation in respect of which the Minister is, after consultation with the council, of the opinion that the public interest requires it to be made without delay.

(4) No regulation shall be made under paragraph (xxx) of subsection (1) except in consultation with the Minister of Finance.

(5) Regulations made under subsection (1) (x) may prescribe that any medicine or any component thereof shall comply with the requirements set out in any publication which in the opinion of the council is generally recognized as authoritative.

(6) Regulations may be made under this section in respect of particular medicines or Scheduled substances or classes or categories of medicines or Scheduled substances or in respect of medicines or Scheduled substances other than particular classes or categories of medicines or Scheduled substances, and different regulations may be so made in respect of different medicines or Scheduled substances or different classes or categories of medicines or Scheduled substances.

(7) Any regulations made under this section may prescribe penalties for any contravention thereof or failure to comply therewith, not exceeding a fine of five hundred rand or imprisonment for a period of six months.".

(2) Any regulation which was in force under section 35 of the principal Act immediately prior to the commencement of subsection (1), shall remain in force until it is amended or withdrawn under the said section 35.

Amendment of section 36 of Act 101 of 1965.

**32.** Section 36 of the principal Act is hereby amended by the substitution for the word "drug" of the word "medicine".

Substitution of section 37 of Act 101 of 1965.

**33.** The following section is hereby substituted for section 37 of the principal Act:

"Medicines manufactured for export.

**37.** Notwithstanding anything to the contrary in this Act contained, the provisions of this Act relating to the registration of medicines shall not apply in respect of any medicine or any quantity of any medicine which is manufactured in or imported into the Republic or the territory solely for the purpose of export from the Republic or the territory and is not used or disposed of for use in the Republic or the territory and in respect of which the council has granted a certificate that it is satisfied in regard to its quality, purity and safety.".

Wet No. 65, 1974 WYSIGINGSWET OP DIE BEHEER VAN MEDISYNE, 1974.

Invoeging van artikel 37A in Wet 101 van 1965.

**34.** Die volgende artikel word hierby in die Hoofwet na artikel 37 ingevoeg:

„Wysiging van Bylaes.

**37A.** Die Minister kan op aanbeveling van die raad enige Bylae by hierdie Wet van tyd tot tyd by kennisgewing in die *Staatskoerant* wysig deur 'n medisyne of ander stof daarby in te sluit of daaruit te skrap, of op enige ander wyse.".

Vervanging van artikel 40 van Wet 101 van 1965.

**35.** Artikel 40 van die Hoofwet word hierby deur die volgende artikel vervang:

„Kort titel.

**40.** Hierdie Wet heet die Wet op die Beheer van Medisyne en Verwante Stowwe, 1965.".

Byvoeging van Bylaes by Wet 101 van 1965.

**36.** Bylaes A, B, C, D, E, F, G, H en I by hierdie Wet word hierby as onderskeidelik Bylaes 1, 2, 3, 4, 5, 6, 7, 8 en 9 by die Hoofwet gevoeg.

Vervanging van lang titel van Wet 101 van 1965.

**37.** Die lang titel van die Hoofwet word hierby deur die volgende lang titel vervang:

„WET

Om voorsiening te maak vir die registrasie van medisyne bestem vir menslike gebruik, vir die instelling van 'n Medisynebeheerraad, vir beheer oor medisyne en gelyste stowwe en vir aangeleenthede wat daarmee in verband staan.".

Herroeping van sekere bepalings van Wet 13 van 1928.

**38.** (1) Artikels 48 tot 72 van en die Vierde en Sesde Bylaes by die Wet op Geneeshere, Tandartse en Aptekers, 1928, word hierby herroep.

(2) Enigiets gedoen ingevolge 'n bepaling by subartikel (1) herroep, word, indien dit ingevolge 'n bepaling van die Hoofwet soos by hierdie Wet gewysig, gedoen kon word, geag ingevolge sodanige laasgenoemde bepaling gedoen te gewees het.

Kort titel en inwerkingtreding.

**39.** Hierdie Wet heet die Wysigingswet op die Beheer van Medisyne, 1974, en tree in werking op 'n datum wat die Staatspresident by proklamasie in die *Staatskoerant* bepaal.

---

## Bylae A

(BYLAE 1 BY WET NO. 101 VAN 1965.)

Alle preparate of mengsels wat nie ingesluit is in Bylae 2 nie en wat 'n stof bevat wat in hierdie Bylae of Bylae 2 gelys is, *uitgesonderd* stowwe, preparate of mengsels wat spesiaal uitgesluit is uit hierdie Bylae.

Alklofenak.
Alle preparate vir inspuiting, tensy anders gelys.
Amielnitriet.
Anetooltritioon.
Antibiotika vir uitwendige gebruik wat uitgesonder is van die bepalings van Bylae 5.
Antikoagulante; preparate en mengsels daarvan bedoel vir uitwendige gebruik.
Antimalariamiddels; preparate wat stowwe bevat in die 4-aminokinolien, 8-aminokinolien, diguanied en diaminopirimidien groepe van verbindings, wanneer spesiaal bedoel vir die voorkoming van malaria.
Asetanilied en alkielasetaniliede.
Asetieldihidrokodeïen; preparate wat 2,5 persent of minder asetieldihidrokodeïen bevat.
Barbituursuur, sy soute of derivate en soute van barbituursuur derivate; mengsels daarvan wat 15 milligram of minder per minimum voorgeskrewe of aanbevole dosis bevat van enige van hierdie in kombinasie met ander medisynes, en die mengsels bedoel slegs vir aanhoudende gebruik in asma en epilepsie.
Beta-aminopropielbenseen en beta-aminoisopropielbenseen; die preparate en mengsels daarvan wat vrygestel is van die bepalings van Bylae 6.
Chloormesanoon; mengsels daarvan wat 100 milligram of minder per minimum aanbevole of voorgeskrewe dosis bevat.
Chloroform; alle stowwe, preparate of mengsels wat meer as 20 persent chloroform bevat.
Defenoksilaat; mengsels wat 2,5 milligram of minder defenoksilaat, as basis bereken, per doseringseenheid bevat.
Disiklomien en sy soute.
Epinefrien en sy soute.

Insertion of section 37A in Act 101 of 1965.

**34.** The following section is hereby inserted in the principal Act after section 37:

"Amendment of Schedules.

**37A.** The Minister may, on the recommendation of the council, from time to time by notice in the *Gazette* amend any Schedule to this Act by the inclusion therein or the deletion therefrom of any medicine or other substance, or in any other manner.".

Substitution of section 40 of Act 101 of 1965.

**35.** The following section is hereby substituted for section 40 of the principal Act:

"Short title.

**40.** This Act shall be called the Medicines and Related Substances Control Act, 1965.".

Addition of Schedules to Act 101 of 1965.

**36.** Schedules A, B, C, D, E, F, G, H and I to this Act are hereby added to the principal Act as Schedules 1, 2, 3, 4, 5, 6, 7, 8 and 9, respectively, thereto.

Substitution of long title of Act 101 of 1965.

**37.** The following long title is hereby substituted for the long title of the principal Act:

"ACT

To provide for the registration of medicines intended for human use, for the establishment of a Medicines Control Council, for the control of medicines and Scheduled substances and for matters incidental thereto.".

Repeal of certain provisions of Act 13 of 1928.

**38.** (1) Sections 48 to 72 of and the Fourth and Sixth Schedules to the Medical, Dental and Pharmacy Act, 1928, are hereby repealed.

(2) Anything done in terms of a provision repealed by subsection (1) shall, if it could be done in terms of a provision of the principal Act as amended by this Act, be deemed to have been done in terms of such last-mentioned provision.

Short title and commencement.

**39.** This Act shall be called the Drugs Control Amendment Act, 1974, and shall come into operation on a date fixed by the State President by proclamation in the *Gazette*.

---

## Schedule A

(SCHEDULE 1 TO ACT NO. 101 OF 1965.)

All preparations and admixtures which are not included in Schedule 2 and contain a substance listed in this Schedule or in Schedule 2, *except* substances, preparations and admixtures excluded specifically from this Schedule.

Acetanilide and alkyl acetanilides.

Acetyldihydrocodeine; preparations containing 2,5 per cent or less acetyldihydrocodeine.

Alclofenac.

All preparations for injection, unless otherwise scheduled.

Amyl nitrite.

Anethole trithione.

Antibiotics for external use which are exempted from the provisions of Schedule 5.

Anticoagulants; preparations and admixtures thereof intended for external use.

Antimalarials; preparations containing substances in the 4-aminoquinoline, 8-aminoquinoline, diguanide and diaminopyrimidine groups of compounds when intended specifically for malaria prophylaxis.

Barbituric acid, its salts or derivatives and salts of barbituric acid derivatives; admixtures thereof containing 15 milligrams or less per minimum prescribed or recommended dose of any of these in combination with other medicines and such admixtures intended solely for continued use in asthma and epilepsy.

Beta-aminopropylbenzene and beta-aminoisopropylbenzene; such preparations and admixtures thereof as are exempted from the provisions of Schedule 6.

Camylofin and its salts.

Eskien en sy soute; preparate en mengsels daarvan bedoel vir uitwendige gebruik wat 1,0 persent of minder eskien bevat.
Etakridien en sy soute.
Eter (diëtieleter).
Etielfenielefrien.
Etielmorfien; mengsels wat 2,5 persent of minder etielmorfien bevat.
Fenasetien.
Fenielefrien en sy soute; preparate en mengsels daarvan, *uitgesonderd* oogdruppels wat 0,2 persent of minder Fenielefrien of sy soute bevat.
Fenoterol en sy soute.
Flufenaamsuur en sy soute; preparate en mengsels daarvan bedoel vir uitwendige gebruik.
Folkodien; mengsels wat 2,5 persent of minder folkodien bevat.
Heksamien.
Heksoprenalien en sy soute.
Hormone (natuurlik of sinteties); die preparate daarvan wat bedoel is slegs vir plaaslike aanwending aan die epidermis of vir vaginale gebruik.
Isoproterenol en sy soute.
Kaliumdikromaat.
Kamilofien en sy soute.
Ketoprofen.
Kinien en sy soute; preparate en mengsels daarvan wat meer as 1,0 persent bevat.
Klonidien en sy soute; preparate en mengsels daarvan wanneer bedoel vir die behandeling van migraine.
Kodeïen (metielmorfien); mengsels wat 2,5 persent of minder kodeïen bevat.
Kokaïen; preparate wat 0,1 persent of minder kokaïen, bereken as kokaïen alkaloïed, bevat.
Kresol en fenol; alle preparate en mengsels wat 3,0 persent of meer van enige van hierdie stowwe bevat.
Kwikammoniumchloried.
Kwikjodied.
Kwikoksiede; stowwe, preparate en mengsels daarvan, *uitgesonderd* dié wat minder as 3,0 persent kwik bevat.
Lokale anestetika; preparate vir plaaslike aanwending aan die vel of slymvliese.
Loodasetaat.
Loodpleister en sy samestellings.
Metaproterenol en sy soute.
Metielasetanilied.
Morfien; mengsels wat 0,2 persent of minder morfien, bereken as anhidriese morfien, bevat.
Naprokseen.
Natriumchromoglikaat.
Nonoksinol.
Orale antidiabetiese preparate.
Pirasetam.
Piridoksilaat; preparate en mengsels daarvan.
Propielheksidrien en sy soute; neusdruppels en preparate vir inhalasie wat bogenoemde stowwe bevat.
Sulfonamiede; preparate en mengsels daarvan bedoel vir uitwendige gebruik.
Terbutalien en sy soute.
Tretinoïen.

---

## Bylae B

(Bylae 2 by Wet No. 101 van 1965.)

Alkaloïede en glikosiede; alle giftige alkaloïede en glikosiede, en hulle soute, wat nie uitdruklik in enige Bylae genoem word nie; stowwe, preparate en mengsels wat in elke enkele dosis meer as die helfte van die maksimum dosis van die vergif bevat soos aangetoon in 'n erkende formulierboek wat deur die Minister by kennisgewing in die *Staatskoerant* as sodanig verklaar is.
Akonietalkaloïede; stowwe, preparate en mengsels wat 0,02 persent of meer bevat.
Antihistaminika, *uitgesonderd* wanneer spesiaal bedoel vir die behandeling van reissiekte of plaaslike gebruik.
Antimoonkaliumtartraat en antimoonnatriumtartraat; stowwe, preparate en mengsels wat 1,0 persent of meer daarvan bevat.
Antipirien (fenasoon) en sy soute; preparate en mengsels daarvan, *uitgesonderd* preparate en mengsels bedoel vir uitwendige gebruik.
Apomorfien; stowwe, preparate en mengsels wat 0,2 persent of meer bevat.
Aptokaïen en sy soute; preparate en mengsels daarvan.
Arseen; stowwe, preparate en mengsels wat 0,01 persent of meer van die ekwivalent van arseentrioksied bevat.
„AS XVII" (‚Spasmo-urgenin').
Atropien; stowwe, preparate en mengsels wat 0,1 persent of meer bevat.
Belladonna-alkaloïede; stowwe, preparate en mengsels wat 0,1 persent of meer bevat, *uitgesonderd* belladonnapleisters.
Braakneut; stowwe, preparate en mengsels wat 0,2 persent of meer strignien bevat.
Camphorated Opium Tincture B.P.
Chloroform.
Dekstrometorfan en sy soute.
Dimenhidrinaat; preparate en mengsels daarvan.
Dipiridamool.
Ditiasanien en sy soute; preparate en mengsels daarvan.

Chlormezanone; admixtures thereof containing 100 milligrams or less per minimum recommended or prescribed dose.
Chloroform; all substances, preparations and admixtures containing more than 20 per cent.
Clonidine and its salts; preparations and admixtures thereof when intended for the treatment of migraine.
Cocaine; preparations containing 0,1 per cent or less cocaine, calculated as cocaine alkaloid.
Codeine (methylmorphine); admixtures containing 2,5 per cent or less codeine.
Cresol and phenol; all preparations and admixtures containing 3,0 per cent or more of any one of these substances.
Dicyclomine and its salts.
Diphenoxylate; admixtures containing 2,5 milligrams or less of diphenoxylate, calculated as base, per dosage unit.
Epinephrine and its salts.
Escin (aescin) and its salts; preparations and admixtures thereof intended for external use and containing 1,0 per cent or less escin.
Ethacridine and its salts.
Ether (diethyl ether).
Ethylmorphine; admixtures containing 2,5 per cent or less ethylmorphine.
Ethylphenylephrine.
Fenoterol and its salts.
Flufenamic acid and its salts; preparations and admixtures thereof intended for external use.
Hexamine.
Hexoprenaline and its salts.
Hormones (natural or synthetic); such preparations thereof intended solely for topical application to the epidermis or for vaginal use.
Isoproterenol and its salts.
Ketoprofen.
Lead acetate.
Lead plaster and its combinations.
Local anaesthetics; preparations for topical application to the skin or mucous membranes.
Mercuric iodide.
Mercuric oxides; substances, preparations and admixtures thereof *except* those containing less than 3,0 per cent of mercury.
Mercuric ammonium chloride.
Metaproterenol and its salts.
Methylacetanilide.
Morphine; admixtures containing 0,2 per cent or less morphine calculated as anhydrous morphine.
Naproxen.
Nonoxynol.
Oral antidiabetic preparations.
Phenacetin.
Phenylephrine and its salts; preparations and admixtures thereof, *except* eye drops containing 0,2 per cent or less phenylephrine or its salts.
Pholcodine; admixtures containing 2,5 per cent or less pholcodine.
Piracetam.
Potassium dichromate.
Propylhexedrine and its salts; nose drops and preparations for inhalation containing the above substances.
Pyridoxilate; preparations and admixtures thereof.
Quinine and its salts; preparations and admixtures thereof containing more than 1,0 per cent.
Sodium cromoglycate.
Sulfonamides; preparations and admixtures thereof intended for external use.
Terbutaline and its salts.
Tretinoin.

---

## Schedule B

(SCHEDULE 2 TO ACT NO. 101 OF 1965.)

Aconite alkaloids; substances, preparations and admixtures containing 0,02 per cent or more.
Alkaloids and glycosides; all poisonous alkaloids and glycosides, and their salts, not specifically named in any Schedule; substances, preparations and admixtures containing in each single dose more than one-half of the maximum dose of the poison shown in any recognized formulary declared to be such by the Minister by notice in the *Gazette*.
Antihistaminics, *except* when intended specifically for the treatment of travel sickness or topical application.
Antimony potassium tartrate and antimony sodium tartrate; substances, preparations and admixtures containing 1,0 per cent or more thereof.
Antipyrine (phenazone) and its salts; preparations and admixtures thereof, *except* preparations and admixtures intended for external use.
Apomorphine; substances, preparations and admixtures containing 0,2 per cent or more.
Aptocaine and its salts; preparations and admixtures thereof.
Arsenic; substances, preparations and admixtures containing 0,01 per cent or more of the equivalent of arsenic trioxide.
"AS XVII" (Spasmo-urgenin).
Atropine; substances, preparations and admixtures containing 0,1 per cent or more.
Belladonna alkaloids; substances, preparations and admixtures containing 0,1 per cent or more, *except* belladonna plasters.
Calabar bean alkaloids and their salts; substances, preparations and admixtures containing 0,2 per cent or more.
Calcium dobesilate.
Camphorated Opium Tincture B.P.

Efedra-alkaloïede (natuurlik of sinteties) en hulle soute; stowwe, preparate en mengsels daarvan, *uitgesonderd* preparate en mengsels vir uitwendige gebruik met hoogstens 1,0 persent, en ander preparate en mengsels met hoogstens 30 milligram per dosis efedrien of efedra-alkaloïede.
Emeproniumbromied.
Epinefrien (adrenalien) en sy soute; preparate en mengsels daarvan.
Ergotalkaloïede (natuurlik of sinteties) en hulle soute; preparate en mengsels daarvan.
Fenielefrien en sy soute; preparate en mengsels van bogenoemde stowwe, *uitgesonderd* oogdruppels wat 0,2 persent of minder daarvan bevat.
Fenielpropanolamien; preparate en mengsels daarvan.
Fenoterol en sy soute; preparate en mengsels daarvan.
Flavoksaathidrochloried.
Flusitosien; preparate en mengsels daarvan wanneer bedoel vir uitwendige gebruik.
Furasolidoon en sy soute; preparate en mengsels daarvan.
Gelseniumalkaloïede; stowwe, preparate en mengsels wat 0,1 persent of meer bevat.
Glikopirroniumbromied.
Harsolie van Aspidium (Filix Mas); preparate en mengsels daarvan.
Heksoprenalien en sy soute; preparate en mengsels daarvan.
Hiossien; stowwe, preparate en mengsels wat 0,1 persent of meer bevat.
Inasemingsmiddels wat epinefrien, fenoterol, heksoprenalien, isoproterenol, metaproterenol, salbutamol of die soute van bovermelde stowwe in enige hoeveelheid bevat.
Isoprenalien (isoproterenol) en sy soute; preparate en mengsels daarvan.
Kalabarboontjies-alkaloïede en hulle soute; stowwe, preparate en mengsels wat 0,2 persent of meer bevat.
Kalsiumdobesilaat.
Kantaridien; stowwe, preparate en mengsels wat 0,01 persent of meer bevat.
Kwikchloried; stowwe, preparate en mengsels wat 1,0 persent of meer bevat.
Kwikorganiese verbindings; preparate en mengsels daarvan, *uitgesonderd* stowwe, preparate en mengsels wat nie in aërosolpreparate vervat is nie, wat bedoel is vir plaaslike aanwending aan die vel of slymvliese en wat minder as die ekwivalent van 0,6 persent kwik (Hg) bevat.
Lobelia-alkaloïede; stowwe, preparate en mengsels wat 0,5 persent of meer bevat.
Metaproterenol (Orsiprenalien) en sy soute; preparate en mengsels daarvan.
Naloksoonhidrochloried.
Nitrofurasoon en sy soute; preparate en mengsels daarvan.
Papaverien; stowwe, preparate en mengsels wat 0,2 persent of meer bevat.
Pilokarpien; stowwe, preparate en mengsels wat 0,5 persent of meer bevat.
Pimetikseen.
Pirodifeniumbromied.
Prokaïen en sy soute wanneer inwendig gebruik.
Propifenasoon; preparate en mengsels daarvan.
Prosiklidien en sy soute; preparate en mengsels daarvan.
Sabadilla-alkaloïede; stowwe, preparate en mengsels wat 1,0 persent of meer bevat.
Siklandelaat.
Siklopentolaat.
Strignien; stowwe, preparate en mengsels wat 0,2 persent of meer bevat.

---

## Bylae C

(BYLAE 3 BY WET NO. 101 VAN 1965.)

Allopurinol; preparate en mengsels daarvan.
Chromonar en sy soute; preparate en mengsels daarvan.
Digitalis, sy glikosiede en ander aktiewe bestanddele daarvan, tensy verdun benede een eenheid (B.P.) in elke twee gram.
Fenitoïen en sy soute; preparate en mengsels daarvan.
Insulien; preparate en mengsels daarvan.
Isoniasied en sy derivate; preparate en mengsels daarvan.
Klofibraat; preparate en mengsels daarvan.
Para-aminosalisielsuur en sy soute en esters; preparate en mengsels daarvan.
Skildklier en sy aktiewe bestanddele en derivate; preparate en mengsels daarvan.
Strofantus, sy glikosiede en hulle hidrolitiese produkte, hulle soute en derivate; preparate en mengsels daarvan.
Trimetadioon; preparate en mengsels daarvan.

---

## Bylae D

(BYLAE 4 BY WET NO. 101 VAN 1965.)

Alprenalol en sy soute; preparate en mengsels daarvan.
Amantadien en sy soute; preparate en mengsels daarvan.
Aminopirien (amidopirien) en sy soute; preparate en mengsels daarvan.
Antihemofilitiese Faktor; preparate en mengsels daarvan.
Antimalariamiddels; preparate daarvan, *uitgesonderd* die 4-aminokinolien-, 8-aminokinolien-, diguanied- en diaminopirimidien-groepe van verbindings en preparate daarvan wanneer spesiaal bedoel vir die voorkoming van malaria.

Cantharidin; substances, preparations and admixtures containig 0,01 per cent or more
Chloroform.
Cyclandelate.
Cyclopentolate.
Dextromethorphan and its salts.
Dimenhydrinate; preparations and admixtures thereof.
Dipyridamole.
Dithiazanine and its salts; preparations and admixtures thereof.
Emepronium bromide.
Ephedra alkaloids (natural or synthetic) and their salts; substances, preparations and admixtures thereof, *except* preparations and admixtures for external use containing not more than one per cent, and other preparations and admixtures containing not more than 30 milligrams per dose of ephedrine or ephedra alkaloids.
Epinephrine (adrenaline) and its salts; preparations and admixtures thereof.
Ergot alkaloids (natural or synthetic) and their salts; preparations and admixtures thereof.
Fenoterol and its salts; preparations and admixtures thereof.
Flavoxate hydrochloride.
Flucytosine; preparations and admixtures thereof when intended for external use.
Furazolidone and its salts; preparations and admixtures thereof.
Gelsenium alkaloids; substances, preparations and admixtures containing 0,1 per cent or more.
Glycopyrronium bromide.
Hexoprenaline and its salts; preparations and admixtures thereof.
Hyoscine; substances, preparations and admixtures containing 0,1 per cent or more.
Inhalants containing epinephrine, fenoterol, hexoprenaline, isoproterenol, metaproterenol, salbutamol or the salts of the above substances in any amount.
Isoprenaline (isoproterenol) and its salts; preparations and admixtures thereof.
Lobelia alkaloids; substances, preparations and admixtures containing 0,5 per cent or more.
Metaproterenol (Orciprenaline) and its salts; preparations and admixtures thereof.
Mercuric chloride; substances, preparations and admixtures containing one per cent or more.
Mercuric organic compounds; preparations and admixtures thereof, *except* substances, preparations and admixtures not being in the form of aerosols intended for topical application to the skin or mucous membranes and containing less than the equivalent of 0,6 per cent of mercury.
Naloxone hydrochloride.
Nitrofurazone and its salts; preparations and admixtures thereof.
Nux vomica; substances, preparations and admixtures containing 0,2 per cent or more of strychnine.
Oleoresin of Aspidium (Filix Mas); preparations and admixtures thereof.
Papaverine; substances, preparations and admixtures containing 0,2 per cent or more.
Phenylephrine and its salts; preparations and admixtures of the above substances, *except* eye drops containing 0,2 per cent or less thereof.
Phenylpropanolamine; preparations and admixtures thereof.
Pilocarpine; substances, preparations and admixtures containing 0,5 per cent or more.
Pimethixene.
Procaine and its salts when used internally.
Procyclidine and its salts; preparations and admixtures thereof.
Propyphenazone; preparations and admixtures thereof.
Pyrodifenium bromide.
Sabadilla alkaloids; substances, preparations and admixtures containing 1,0 per cent or more.
Strychnine; substances, preparations and admixtures containing 0,2 per cent or more.

## Schedule C

(SCHEDULE 3 TO ACT NO. 101 OF 1965.)

Allopurinol; preparations and admixtures thereof.
Chromonar and its salts; preparations and admixtures thereof.
Clofibrate; preparations and admixtures thereof.
Digitalis, its glycosides and other active principles thereof unless diluted below one unit (B.P.) in each two grams.
Insulin; preparations and admixtures thereof.
Isoniazid and its derivatives; preparations and admixtures thereof.
Para-aminosalicylic acid and its salts and esters; preparations and admixtures thereof.
Phenytoin and its salts; preparations and admixtures thereof.
Strophanthus, its glycosides and their hydrolysis products, their salts and derivatives; preparations and admixtures thereof.
Thyroid gland and its active principles and derivatives; preparations and admixtures thereof.
Trimethadione; preparations and admixtures thereof.

## Schedule D

(SCHEDULE 4 TO ACT NO. 101 OF 1965.)

Acetazolamide and its salts; preparations and admixtures thereof.
Alprenalol and its salts; preparations and admixtures thereof.
Amantadine and its salts; preparations and admixtures thereof.
Aminopyrine (amidopyrine) and its salts; preparations and admixtures thereof.
Antihemophilic Factor; preparations and admixtures thereof.
Antimalarials; preparations thereof *except* the 4-aminoquinoline, 8-aminoquinoline, diguanide and diaminopyridine groups of compounds and preparations thereof when these are intended specifically for malaria prophylaxis.

**Wet No. 65, 1974** WYSIGINGSWET OP DIE BEHEER VAN MEDISYNE, 1974.

Antimikrobiese stowwe (chemoterapeutiese stowwe) gesintetiseer in die natuur of laboratorium, synde stowwe wat gebruik word in die spesifieke behandeling van infeksies; preparate en mengsels wat bovermelde bevat, *uitgesonderd* die volgende wanneer bedoel vir plaaslike aanwending aan die epidermis:

basitrasien
tirotrisien
nistatien
polimiksien B
framisetien
neomisien
natamisien
gramisidien

en *uitgesonderd* wanneer bedoel vir gebruik as kiemdoder en antiseptika, en *uitgesonderd* die stowwe, preparate en mengsels wat ingevolge die bepalings van die Wet op Misstowwe, Veevoedsel, Landboumiddels en Veemiddels, 1947 (Wet 36 van 1947), geregistreer is en verkoop word.

Asapropasoon; preparate en mengsels daarvan.
Asetasoolamied en sy soute; preparate en mengsels daarvan.
Baklofen; preparate en mengsels daarvan.
Bensbromaroon; preparate en mengsels daarvan.
Bufenoïed; preparate en mengsels daarvan.
Byegif; preparate en mengsels daarvan, *uitgesonderd* preparate vir uitwendige aanwending.
Chloortalidoon en sy soute; preparate en mengsels daarvan.
Chloortiasied en ander derivate van benso-1, 2, 4-tiadiasien-7-sulfoonamied-1, 1-dioksied, gehidrogeneer al dan nie, insluitende hidrochloortiasied, bendrofluasied, benstiasied, siklopentiasied, hidroflumetiasied, metchloortiasied; preparate en mengsels daarvan.
Cholestiramienhars; preparate en mengsels daarvan.
Dapsoon en sy derivate; preparate en mengsels daarvan, *uitgesonderd* preparate wat spesifiek bedoel word vir die voorkoming van malaria, en *uitgesonderd* middels wat geregistreer is kragtens die Wet op Misstowwe, Veevoedsel, Landboumiddels en Veemiddels, 1947 (Wet 36 van 1947).
Debrisokien en sy soute; preparate en mengsels daarvan.
Diasoksied; preparate en mengsels daarvan.
Difemetoksidien en sy soute; preparate en mengsels daarvan.
Difenidol en sy soute; preparate en mengsels daarvan.
Di-isopropielfluoorfosfaat; preparate en mengsels daarvan.
Dimetielsulfoksied; preparate en mengsels daarvan.
Dinitrofenol en sy soute; preparate en mengsels daarvan.
Dipiridamol; preparate en mengsels daarvan.
Disopiramied; preparate en mengsels daarvan.
Disulfiram; preparate en mengsels daarvan.
Dopa; preparate en mengsels daarvan.
Emetien en sy soute; preparate en mengsels daarvan.
Eskien en sy soute; preparate en mengsels daarvan, *uitgesonderd* preparate en mengsels vir uitwendige gebruik wat 1,0 persent of minder eskien bevat.
Etakriensuur en sy soute; preparate en mengsels daarvan.
Etambutol en sy soute; preparate en mengsels daarvan.
Etioonamied; preparate en mengsels daarvan.
Fenielbutasoon en sy soute; preparate en mengsels daarvan, *uitgesonderd* preparate vir plaaslike aanwending aan die epidermis.
Fentolamien en sy soute; preparate en mengsels daarvan.
Flufenaamsuur en sy soute; preparate en mengsels daarvan.
Flusitosien; preparate en mengsels daarvan, *uitgesonderd* preparate en mengsels bedoel vir uitwendige gebruik.
Furosemied; preparate en mengsels daarvan.
Glafenien; preparate en mengsels daarvan.
Guanaklien en sy soute; preparate en mengsels daarvan.
Halofenaat; preparate en mengsels daarvan.
Hormone (natuurlik of sinteties); preparate en mengsels daarvan, *uitgesonderd* daardie preparate en mengsels wat bedoel is slegs vir plaaslike aanwending aan die epidermis, en *uitgesonderd* preparate vir vaginale gebruik, en *uitgesonderd* daardie stowwe wat ingevolge die bepalings van die Wet op Misstowwe, Veevoedsel, Landboumiddels en Veemiddels, 1947 (Wet 36 van 1947), geregistreer is en verkoop word, en *uitgesonderd* insulien en epinefrien (adrenalien).
Indapamied; preparate en mengsels daarvan.
Indometasien en sy soute; preparate en mengsels daarvan.
Kaliumkanrenoaat; preparate en mengsels daarvan.
Karbidopa; preparate en mengsels daarvan.
Klofasimien; preparate en mengsels daarvan.
Klonidien en sy soute; preparate en mengsels daarvan, *uitgesonderd* preparate en mengsels bedoel vir die behandeling van migraine.
Kortikosteroïede (natuurlik of sinteties); preparate en mengsels daarvan.
Lokale anestetika; preparate en mengsels daarvan, *uitgesonderd* preparate vir uitwendige aanwending aan die vel en slymvliese.
Mefenaamsuur en sy soute; preparate en mengsels daarvan.
Mefentermien en sy soute; preparate en mengsels daarvan.
2-Merkaptonielpropionielglisien; preparate en mengsels daarvan.
Metampiroon; preparate en mengsels daarvan.
Metieldopa en sy soute en esters; preparate en mengsels daarvan.
Metisergied en sy soute; preparate en mengsels daarvan.
Morfasienamied en sy soute; preparate en mengsels daarvan.
Morfetielbutynhidrochloried; preparate en mengsels daarvan.
Nalidisiensuur; preparate en mengsels daarvan.
Nalorfienhidrobromied; preparate en mengsels daarvan.
Natriumnitroprussied; preparate en mengsels daarvan.
Niflumiensuur; preparate en mengsels daarvan.

Antimicrobial substances (chemotherapeutic substances) synthesised in nature or laboratory, being substances used in the specific treatment of infections; preparations and admixtures containing them, *except* the following when intended for topical application to the epidermis:

bacitracin
tyrothricin
nystatin
polymixin B
framycetin
neomycin
natamycin
gramicidin

and *except* when intended to be used as germicides and antiseptics, and *except* those substances, preparations and admixtures registered and sold under the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act No. 36 of 1947).

Azapropazone; preparations and admixtures thereof.
Baclofen; preparations and admixtures thereof.
Bee venom; preparations and admixtures thereof, *except* preparations for external application.
Benzbromarone; preparations and admixtures thereof.
Bufenoide; preparations and admixtures thereof.
Carbidopa; preparations and admixtures thereof.
Chlorothiazide and other derivatives of benzo-1, 2, 4-thiadiazine-7-sulfonamide-1, 1-dioxide, whether or not hydrogenated, including hydrochlorothiazide, bendrofluazide, benzthiazide, cyclopenthiazide, hydroflumethiazide, methchlorothiazide; preparations and admixtures thereof.
Chlorthalidone and its salts; preparations and admixtures thereof.
Cholestyramine resin; preparations and admixtures thereof.
Clofazimine; preparations and admixtures thereof.
Chlonidine and its salts; preparations and admixtures thereof, *except* preparations and admixtures intended for the treatment of migraine.
Corticosteroids (natural or synthetic); preparations and admixtures thereof.
Cyclofenil; preparations and admixtures thereof.
Dapsone and its derivatives; preparations and admixtures thereof, *except* preparations intended specifically for malaria prophylaxis and *except* products which are registered under the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act No. 36 of 1947).
Debrisoquine and its salts; preparations and admixtures thereof.
Diazoxide; preparations and admixtures thereof.
Di-isopropyl fluorophosphate; preparations and admixtures thereof.
Dimethyl sulfoxide; preparations and admixtures thereof.
Dinitrophenol and its salts; preparations and admixtures thereof.
Diphemethoxidine and its salts; preparations and admixtures thereof.
Diphenidol and its salts; preparations and admixtures thereof.
Dipyridamole; preparations and admixtures thereof.
Disopyramide; preparations and admixtures thereof.
Disulfiram; preparations and admixtures thereof.
Dopa; preparations and admixtures thereof.
Emetine and its salts; preparations and admixtures thereof.
Escin (aescin) and its salts; preparations and admixtures thereof, *except* preparations and admixtures for external use containing 1,0 or less percent escin.
Ethacrynic acid and its salts; preparations and admixtures thereof.
Ethambutol and its salts; preparations and admixtures thereof.
Ethionamide; preparations and admixtures thereof.
Eyedrops containing local anaesthetics.
Flucytosine; preparations and admixtures thereof, *except* preparations and admixtures intended for external use.
Flufenamic acid and its salts; preparations and admixtures thereof, *except* preparations and admixtures intended for external use.
Furosemide; preparations and admixtures thereof.
Glaphenine; preparations and admixtures thereof.
Guanacline and its salts; preparations and admixtures thereof.
Halofenate; preparations and admixtures thereof.
Hormones (natural or synthetic); preparations and admixtures thereof, *except* those preparations and admixtures intended solely for topical application to the epidermis, and *except* preparations for vaginal use, and *except* those registered and sold under the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act No. 36 of 1947), and *except* insulin and epinephrine (adrenaline).
Indapamide; preparations and admixtures thereof.
Indomethacin and its salts; preparations and admixtures thereof.
Local anaesthetics; preparations and admixtures thereof, *except* preparations for external application to the skin and mucous membranes.
Mefenamic acid and its salts; preparations and admixtures thereof.
Mephentermine and its salts; preparations and admixtures thereof.
2-Mercaptonylpropionylglycine; preparations and admixtures thereof.
Methampyrone; preparations and admixtures thereof.
Methyldopa and its salts and esters; preparations and admixtures thereof.
Methysergide and its salts; preparations and admixtures thereof.
Morphazinamide and its salts; preparations and admixtures thereof.
Morphethylbutyne hydrochloride; preparations and admixtures thereof.
Nalidixic acid; preparations and admixtures thereof.
Nalorphine hydrobromide; preparations and admixtures thereof.
Niflumic acid; preparations and admixtures thereof.

Niridasool; preparate en mengsels daarvan.
Nitrofurantoïen en sy soute; preparate en mengsels daarvan.
Nitroksolien en sy soute; preparate en mengsels daarvan.
Oksoliensuur; preparate en mengsels daarvan.
Oksprenalol en sy soute; preparate en mengsels daarvan.
Oogdruppels wat lokale anestetika bevat.
Pankuronium en sy soute; preparate en mengsels daarvan.
Penisillamien; preparate en mengsels daarvan.
Pentoksiefillien; preparate en mengsels daarvan.
Perheksilienmaleaat; preparate en mengsels daarvan.
Pikrotoksien; preparate en mengsels daarvan.
Pirasienamied; preparate en mengsels daarvan.
Poligliserileendekstran en sy soute; preparate en mengsels daarvan.
Praktolol en sy soute; preparate en mengsels daarvan.
Prasosien en sy soute; preparate en mengsels daarvan.
Prindolol; preparate en mengsels daarvan.
Prokaïenamied; preparate en mengsels daarvan.
Propaandiol derivate en hulle soute; preparate en mengsels daarvan, *uitgesonderd* guaifenesien en chlorfenesien.
Propielheksedrien en sy soute; preparate en mengsels daarvan, *uitgesonderd* wanneer gebruik as 'n bloedvatvernouer en ontstuwer in neusdruppels en toestelle vir inaseming.
Propranolol en sy soute; preparate en mengsels daarvan.
Protionamied; preparate en mengsels daarvan.
Rauwolfia serpentina; preparate en mengsels wat 0,1 persent of meer van sy alkaloïede of hulle derivate bevat.
Siklofeniel; preparate en mengsels daarvan.
Stiramaat; preparate en mengsels daarvan.
Sulfonamiede; stowwe, preparate en mengsels daarvan, *uitgesonderd* dié stowwe, preparate en mengsels bedoel vir uitwendige gebruik, en *uitgesonderd* die stowwe, preparate en mengsels wat ingevolge die bepalings van die Wet op Misstowwe, Veevoedsel, Landboumiddels en Veemiddels, 1947 (Wet 36 van 1947), geregistreer is en verkoop word.
Tamoksifeen en sy soute; preparate en mengsels daarvan.
Tiasetasoon; preparate en mengsels daarvan.
Tilidien en sy soute; preparate en mengsels daarvan.
Toksogonien en sy soute; preparate en mengsels daarvan.
Traneksamiensuur; preparate en mengsels daarvan.
Triamtireen.
Verapamiel (iproveratriel) en sy soute; preparate en mengsels daarvan.
Veratrum alkaloïede; preparate en mengsels daarvan.

## Bylae E

(BYLAE 5 BY WET NO. 101 VAN 1965.)

Amitriptilien en sy derivate en hulle soute; preparate en mengsels daarvan.
Anestetiese preparate wat pregnaandioon derivate bevat.
Antistolmiddels; preparate en mengsels daarvan, *uitgesonderd* wanneer dit as knaagdier- of wurmdoders gebruik word, en *uitgesonderd* preparate vir uitwendige aanwending.
Aponal; preparate en mengsels daarvan.
Apronalied; preparate en mengsels daarvan.
Asasiklonol en sy soute; preparate en mengsels daarvan.
L-Aspariginase; preparate en mengsels daarvan.
Barbituursuur, sy derivate en soute daarvan; preparate en mengsels daarvan *uitgesonderd* preparate en mengsels wat 15 milligram of minder per minimum aanbevole of voorgeskrewe dosis van enige van bovermelde in kombinasie met ander medisynes bevat, en *uitgesonderd* mengsels wat nie meer as 30 milligram per minimum aanbevole of voorgeskrewe dosis bevat nie, wanneer bedoel vir aanhoudende gebruik in asma en epilepsie.
Benaktisien, sy derivate en hulle soute; preparate en mengsels daarvan.
Benskinamied en sy soute; preparate en mengsels daarvan.
Bensoktamien en sy soute; preparate en mengsels daarvan.
Beta-aminopropielbenseen en beta-amino-isopropielbenseen en enige verbinding struktureel afkomstig van enigeen van hierdie twee stowwe deur substitusie in die syketting of deur ringsluiting daarin (of deur sodanige substitusie sowel as ringsluiting) enige sout of stof wat hieronder val, en preparate en mengsels daarvan (*uitgesonderd* preparate en mengsels van bostaande wanneer dit gebruik word as bloedvatvernouers en ontstuwers in antihistamienneusdruppels en -oogdruppels, en *uitgesonderd* wanneer dit voorkom in toestelle vir inaseming waarin die stof in soliede materiaal geabsorbeer is, en *uitgesonderd* efedrien, N-diëtielamino-etielefedrien, etafedrien, fenielpropanolamien, N-metielefedrien, prenilamien, en preparate en mengsels daarvan.).
Bromasepam; preparate en mengsels daarvan.
Bromisovalum; preparate en mengsels daarvan.
Busulfaan en sy soute; preparate en mengsels daarvan.
Butirofenone; preparate en mengsels daarvan.
Butriptilien en sy soute; preparate en mengsels daarvan.
Chloorambusiel en sy soute; preparate en mengsels daarvan.
Chloordiasepoksied en sy soute; preparate en mengsels daarvan.
Chloormesanoon; preparate en mengsels daarvan, *uitgesonderd* preparate wat 100 milligram of minder chloormesanoon per minimum aanbevole of voorgeskrewe dosis bevat.
Chloraal derivate; preparate en mengsels daarvan.
Deanol en sy derivate; preparate en mengsels daarvan.
Dekstropropoksifeen en sy soute; preparate en mengsels daarvan.
Diasepam; preparate en mengsels daarvan.
Dibensepien en sy soute; preparate en mengsels daarvan.

Niridazole; preparations and admixtures thereof.
Nitrofurantoin and its salts; preparations and admixtures thereof.
Nitroxoline and its salts; preparations and admixtures thereof.
Oxolinic acid; preparations and admixtures thereof.
Oxprenalol and its salts; preparations and admixtures thereof.
Pancuronium and its salts; preparations and admixtures thereof.
Penicillamine; preparations and admixtures thereof.
Pentoxifylline; preparations and admixtures thereof.
Perhexiline maleate; preparations and admixtures thereof.
Phentolamine and its salts; preparations and admixtures thereof.
Phenylbutazone and its salts; preparations and admixtures thereof, *except* preparations for topical application to the epidermis.
Picrotoxin; preparations and admixtures thereof.
Polyglycerylene-dextran and its salts; preparations and admixtures thereof.
Potassium canrenoate; preparations and admixtures thereof.
Practolol and its salts; preparations and admixtures thereof.
Prazosin and its salts; preparations and admixtures thereof.
Prindolol; preparations and admixtures thereof.
Procaine amide; preparations and admixtures thereof.
Propanediol derivatives and their salts; preparations and admixtures thereof, *except* guaiphenesin and chlorphenesin.
Propranolol and its salts; preparations and admixtures thereof.
Propylhexedrine and its salts; preparations and admixtures thereof, *except* when used as a vasoconstrictor and decongestant in nose drops and appliances for inhalation.
Protionamide; preparations and admixtures thereof.
Pyrazinamide; preparations and admixtures thereof.
Rauwolfia serpentina; preparations and admixtures containing 0,1 or more percent of its alkaloids or their derivatives.
Sodium nitroprusside; preparations and admixtures thereof.
Styramate; preparations and admixtures thereof.
Sulfonamides; substances, preparations and admixtures thereof, *except* those substances, preparations and admixtures intended for external use, and *except* those substances, preparations and admixtures registered and sold under the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act No. 36 of 1947).
Tamoxifen and its salts; preparations and admixtures thereof.
Thiacetazone; preparations and admixtures thereof.
Tilidine and its salts; preparations and admixtures thereof.
Toxogonin and its salts; preparations and admixtures thereof.
Tranexamic acid; preparations and admixtures thereof.
Triamterene.
Verapamil (iproveratril) and its salts; preparations and admixtures thereof.
Veratrum alkaloids; preparations and admixtures thereof.

---

## Schedule E

(SCHEDULE 5 TO ACT NO. 101 OF 1965.)

Amitryptiline and its derivatives and their salts; preparations and admixtures thereof.
Anaesthetic preparations containing pregnanedione derivatives.
Anticoagulants; preparations and admixtures thereof, *except* when used as rodenticides and vermicides, and *except* preparations for external application.
Aponal; preparations and admixtures thereof.
Apronalide; preparations and admixtures thereof.
L-Asparaginase; preparations and admixtures thereof.
Azacyclonol and its salts; preparations and admixtures thereof.
Barbituric acid, its derivatives and salts thereof; preparations and admixtures thereof, *except* when containing 15 or less milligrams per minimum recommended or prescribed dose of any of these in combination with other medicines and *except* admixtures containing not more than 30 milligrams per minimum recommended or prescribed dose where intended for continued use in asthma and epilepsy.
Benactyzine, its derivatives and their salts; preparations and admixtures thereof.
Benzoctamine and its salts; preparations and admixtures thereof.
Benzquinamide and its salts; preparations and admixtures thereof.
Beta-aminopropylbenzene and beta-aminoisopropylbenzene, and any compound structurally derived from either of these substances by substitution in the side chain or by ring closure therein (or by both such substitution and ring closure) and any salt or substance falling under the above and preparations and admixtures thereof (*except* preparations and admixtures of the above when used as vasoconstrictors and decongestants in antihistamine nasal and eye drops, and *except* when contained in appliances for inhalation in which the substance is absorbed in solid material, and *except* ephedrine, etafedrine, N-methylephedrine, N-diethylaminoethylephedrine, phenylpropanolamine, prenylamine and preparations and admixtures thereof.)
Bromazepam; preparations and admixtures thereof.
Bromisovalum; preparations and admixtures thereof.
Busulphan and its salts; preparations and admixtures thereof.
Butriptyline and its salts; preparations and admixtures thereof.
Butyrophenones; preparations and admixtures thereof.
Carbamazepine; preparations and admixtures thereof.
Carbromal; preparations and admixtures thereof.
Chloral derivatives; preparations and admixtures thereof.
Chlorambucil and its salts; preparations and admixtures thereof.
Chlordiazepoxide and its salts; preparations and admixtures thereof.
Chlormezanone; preparations and admixtures thereof, *except* admixtures containing 100 or less milligrams of chlormezanone per minimum recommended or prescribed dose.

Dikaliumchloorasepaat; preparate en mengsels daarvan.
Doksepien en sy soute; preparte en mengsels daarvan.
Dotiëpien en sy soute; preparate en mengsels daarvan.
Echotiopaatjodied; preparate en mengsels daarvan.
Enfluraan; preparate en mengsels daarvan.
Etchloorvinol; preparate en mengsels daarvan.
Etinamaat, sy derivate en hulle soute; preparate en mengsels daarvan.
Fenetielhidrasien en sy soute; preparate en mengsels daarvan.
Fenfluramien en sy soute; preparate en mengsels daarvan.
Fenkamfamien en sy soute; preparate en mengsels daarvan.
Fenotiasien, sy derivate en hulle soute; preparate en mengsels daarvan, *uitgesonderd* preparate wat prometasien of sy soute bevat, wanneer dit spesiaal bedoel is vir die behandeling van reissiekte of vir plaaslike aanwending aan die epidermis, en *uitgesonderd* sodanige preparate wat ingevolge die bepalings van die Wet op Misstowwe, Veevoedsel, Landboumiddels en Veemiddels, 1947 (Wet 36 van 1947), geregistreer is en verkoop word.
Fentermien en sy soute; preparate en mengsels daarvan.
5-Fluoorurasiel; preparate en mengsels daarvan.
Flurasepam en sy soute; preparate en mengsels daarvan.
Halotaan.
Hedonal en sy soute en esters; preparate en mengsels daarvan.
Hidroksisien en sy soute; preparate en mengsels daarvan.
Hidroksi-urea; preparate en mengsels daarvan.
Imipramien, sy derivate en hulle soute; preparate en mengsels daarvan.
Iproniasied en sy soute; preparate en mengsels daarvan.
Karbamasepien; preparate en mengsels daarvan.
Karbromal; preparate en mengsels daarvan.
Ketamien en sy soute; preparate en mengsels daarvan.
Klobensasepam; preparate en mengsels daarvan.
Klonasepam; preparate en mengsels daarvan.
Klosapien; preparate en mengsels daarvan.
Klotiapien; preparate en mengsels daarvan.
Litiumsoute; preparate en mengsels daarvan wanneer bedoel vir menslike gebruik.
Lorasepam; preparate en mengsels daarvan.
Maprotilienmesilaat; preparate en mengsels daarvan.
Masindool; preparate en mengsels daarvan.
Medasepam; preparate en mengsels daarvan.
Mefenoksaloon; preparate en mengsels daarvan.
Mefentermien en sy soute; preparate en mengsels daarvan.
Meklofenoksaat en sy soute; preparate en mengsels daarvan.
Melfalan, sy derivate en hulle soute; preparate en mengsels daarvan.
Meprobamaat; preparate en mengsels daarvan.
6-Merkaptopurien, sy derivate en hulle soute; preparate en mengsels daarvan.
Metipriloon en sy soute; preparate en mengsels daarvan.
Metoklopramied.
Molindoon en sy soute; preparate en mengsels daarvan
Nitrasepam; preparate en mengsels daarvan.
Oksasepam; preparate en mengsels daarvan.
Oksipertien en sy soute; preparate en mengsels daarvan.
Paraldehied; preparate en mengsels daarvan.
Pargilien en sy soute; preparate en mengsels daarvan.
Pemolien en sy komplekse; preparate en mengsels daarvan.
Pipradol en sy soute; preparate en mengsels daarvan.
Pregnaandioon.
Prolintaan en sy soute; preparate en mengsels daarvan.
Sulfonmetaan; preparate en mengsels daarvan.
Sulpiried; preparate en mengsels daarvan.
Temasepam; preparate en mengsels daarvan.
Tiotikseen en sy soute; preparate en mengsels daarvan.
Tranielsipromien en sy soute; preparate en mengsels daarvan.
Trasodoon en sy soute; preparate en mengsels daarvan.
Triheksfenidiel en sy soute; preparate en mengsels daarvan.
Uretaan; preparate en mengsels daarvan.

---

## Bylae F

(Bylae 6 by Wet No. 101 van 1965.)

Barbiturate, naamlik amobarbitaal, siklobarbitaal, pentobarbitaal, sekobarbitaal en hulle soute; preparate en mengsels daarvan.
Chloorfentermien en sy soute; preparate en mengsels daarvan.
Diëtielpropioon en sy soute; preparate en mengsels daarvan.
Glutetimied; preparate en mengsels daarvan.
Metakaloon en sy soute; preparate en mengsels daarvan.
Pentasosien en sy soute; preparate en mengsels daarvan.

---

Clobenzazepam; preparations and admixtures thereof.
Clonazepam; preparations and admixtures thereof.
Clothiapine; preparations and admixtures thereof.
Clozapine; preparations and admixtures thereof.
Deanol and its derivatives; preparations and admixtures thereof.
Dextropropoxyphene and its salts; preparations and admixtures thereof.
Diazepam; preparations and admixtures thereof.
Dibenzepin and its salts; preparations and admixtures thereof.
Dipotassium chlorazepate; preparations and admixtures thereof.
Dothiepin and its salts; preparations and admixtures thereof.
Doxepin and its salts; preparations and admixtures thereof.
Echothiopate iodide; preparations and admixtures thereof.
Enflurane; preparations and admixtures thereof.
Ethchlorvynol; preparations and admixtures thereof.
Ethinamate, its derivatives and their salts; preparations and admixtures thereof.
Fencamfamine and its salts; preparations and admixtures thereof.
Fenfluramine and its salts; preparations and admixtures thereof.
5-Fluorouracil; preparations and admixtures thereof.
Flurazepam and its salts; preparations and admixtures thereof.
Halothane.
Hedonal and its salts and esters; preparations and admixtures thereof.
Hydroxyurea; preparations and admixtures thereof.
Hydroxyzine and its salts; preparations and admixtures thereof.
Imipramine, its derivatives and their salts; preparations and admixtures thereof.
Iproniazid and its salts; preparations and admixtures thereof.
Ketamine and its salts; preparations and admixtures thereof.
Lithium salts; preparations and admixtures thereof, when intended for human use.
Lorazepam; preparations and admixtures thereof.
Maprotiline mesylate; preparations and admixtures thereof.
Mazindol; preparations and admixtures thereof.
Meclofenoxate and its salts; preparations and admixtures thereof.
Medazepam; preparations and admixtures thereof.
Melphalan, its derivatives and their salts; preparations and admixtures thereof.
Mephenoxalone; preparations and admixtures thereof.
Mephentermine and its salts; preparations and admixtures thereof.
Meprobamate; preparations and admixtures thereof.
6-Mercaptopurine, its derivatives and their salts; preparations and admixtures thereof.
Methyprylone and its salts; preparations and admixtures thereof.
Metoclopramide.
Molindone and its salts; preparations and admixtures thereof.
Nitrazepam; preparations and admixtures thereof.
Oxazepam; preparations and admixtures thereof.
Oxypertine and its salts; preparations and admixtures thereof.
Paraldehyde; preparations and admixtures thereof.
Pargyline and its salts; preparations and admixtures thereof.
Pemoline and its complexes; preparations and admixtures thereof.
Phenethylhydrazine and its salts; preparations and admixtures thereof.
Phenothiazine, its derivatives and their salts; preparations and admixtures thereof *except* preparations containing promethazine or its salts when specially intended for the treatment of travel sickness or local application to the epidermis, and *except* those registered and sold under the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act No. 36 of 1947).
Phentermine and its salts; preparations and admixtures thereof.
Pipradrol and its salts; preparations and admixtures thereof.
Pregnanedione.
Prolintane and its salts; preparations and admixtures thereof.
Sulfonmethane; preparations and admixtures thereof.
Sulpyride; preparations and admixtures thereof.
Temazepam; preparations and admixtures thereof.
Thiothixene and its salts; preparations and admixtures thereof.
Tranylcypromine and its salts; preparations and admixtures thereof.
Trazodone and its salts; preparations and admixtures thereof.
Trihexyphenidyl and its salts; preparations and admixtures thereof.
Urethan; preparations and admixtures thereof.

---

## Schedule F

(SCHEDULE 6 TO ACT NO. 101 OF 1965.)

Barbiturates, being amobarbital, cyclobarbital, pentobarbital, secobarbital and their salts; preparations and admixtures thereof.
Chlorphentermine and its salts; preparations and admixtures thereof.
Diethylpropion and its salts; preparations and admixtures thereof.
Glutethimide, preparations and admixtures thereof.
Methaqualone and its salts; preparations and admixtures thereof.
Pentazocine and its salts; preparations and admixtures thereof.

---

## Bylae G

(BYLAE 7 BY WET NO. 101 VAN 1965.)

Al die stowwe genoem in hierdie bylae sluit in—

(*a*) die isomere van die stowwe waar die bestaan van sodanige isomere in die bepaalde chemiese samestellings moontlik is;

(*b*) die esters en eters van die stowwe en die isomere daarvan, waar die bestaan van sodanige esters en eters moontlik is;

(*c*) die soute van die stowwe of die isomere daarvan òf van die esters of eters van die stowwe òf die isomere daarvan, waar die bestaan van sodanige soute moontlik is; en

(*d*) alle preparate en mengsels van die stowwe waar sodanige preparate en mengsels nie uitdruklik uitgesluit word nie.

Alfameprodien.
Alfametadol.
Alfaprodien.
Alfasetielmetadol.
Allielprodien.
Anileridien.
Asetieldihidrokodeïen, *uitgesonderd* mengsels wat hoogstens 2,5 persent asetieldihidrokodeïen bevat.
Asetielmetadol.
Asetorfien.
Bensetidien.
Bensfetamien.
Bensielmorfien.
Besitramied.
Betameprodien.
Betametadol.
Betaprodien.
Betasetielmetadol.
Chlorodien (Tinktuur van Chloroform en Morfien B.P.C. 1963) of enige preparaat of mengsel daarvan beskryf as chlorodien en bevattende morfien in enige verhouding, *uitgesonderd* mengsels wat hoogstens 5,0 persent chlorodien in kombinasie met ander medisyne bevat op so 'n wyse dat dit nie deur maklik toepasbare middele herwin kan word nie of nie soveel herwin kan word dat dit 'n gevaar vir die openbare gesondheid inhou nie.
Dekstromoramied.
Desomorfien.
Diampromied.
Diëtieltiambuteen.
Difenoksien (of defenoksiensuur); enige preparaat van defenoksien wat per doseringseenheid 'n maksimum van 0,5 milligram defenoksien, as basis bereken, bevat, en 'n hoeveelheid atropiensulfaat, minstens gelyk aan 5,0 persent van die hoeveelheid difenoksien, as basis bereken, in die mengsel.
Difenoksilaat, *uitgesonderd* mengsels wat hoogstens 2,5 milligram defenoksilaat, as basis bereken, bevat.
Dihidrokodeïen, *uitgesonderd* mengsels wat hoogstens 2,5 persent dihidrokodeïen bevat.
Dihidromorfien.
Dimefeptanol.
Dimenoksadol.
Dimetieltiambuteen.
Dioksafetielbutiraat.
Dipipanoon.
Ekgonien, en die esters en derivate daarvan wat veranderbaar is in ekgonien en kokaïen.
Etielmetieltiambuteen.
Etielmorfien, *uitgesonderd* mengsels wat hoogstens 2,5 persent etielmorfien bevat.
Etokseridien.
Etonitaseen.
Etorfien.
Fenadoksoon.
Fenampromied.
Fenasosien.
Fendimetrasien.
Fenomorfaan.
Fenoperidien.
Fensiklidien.
Fentaniel.
Folkodien, *uitgesonderd* mengsels wat hoogstens 2,5 persent folkodien bevat.
Furetidien.
Hidrokodoon (dihidrokodeïnoon).
Hidroksipetidien.
Hidromorfinol (14-hidroksihidromorfien).
Hidromorfoon (dihidromorfinoon).
Isometadoon.
Ketobemidoon.
Klonitaseen.
Kodeïen (metielmorfien), *uitgesonderd* mengsels wat hoogstens 2,5 persent kodeïen bevat.
Kodoksien.
Kokaïen, *uitgesonderd* mengsels wat hoogstens 0,1 persent kokaïen, bereken as kokaïenalkaloïed, bevat.
Levofenasielmorfaan.
Levomoramied.
Levorfanol.
Mefenoreks.
Metadoon.

## Schedule G

(SCHEDULE 7 TO ACT NO. 101 OF 1965.)

All the substances mentioned in this Schedule include—

(*a*) the isomers of the substances where the existence of such isomers is possible in the specific chemical compounds;

(*b*) the esters and ethers of the substances and the isomers thereof where the existence of such esters and ethers is possible;

(*c*) the salts of the substances or the isomers thereof or of the esters or ethers of the substances or the isomers thereof, where the existence of such salts is possible;

(*d*) all the preparations and admixtures of the substances where such preparations and admixtures are not expressly excluded.

Acetorphine.

Acetyldihidrocodeine, *excluding* admixtures containing not more than 2,5 per cent acetyldihydrocodeine.

Acetylmethadol.

Allylprodine.

Alphacetylmethadol.

Alphameprodine.

Alphamethadol.

Alphaprodine.

Anileridine.

Benzethidine.

Benzphetamine.

Benzylmorphine.

Betacetylmethadol.

Betameprodine.

Betamethadol.

Betaprodine.

Bezitramide.

Chlorodyne (Tincture of Chloroform and Morphine B.P.C. 1963) or any preparation or admixture thereof described as chlorodyne and containing morphine in any proportion, *except* admixtures containing not more than 5,0 per cent chlorodyne in combination with other medicines in such a manner that it cannot be recovered by readily applicable means or cannot be recovered in a yield which would constitute a risk to public health.

Clonitazene.

Cocaine, *excluding* admixtures containing not more than 0,1 per cent cocaine, calculated as cocaine alkaloid.

Codeine (methylmorphine), *excluding* admixtures containing not more than 2,5 per cent codeine.

Codoxime.

Concentrate of poppy straw.

Desomorphine.

Dextromoramide.

Diampromide.

Diethylthiambutene.

Difenoxine (or diphenoxylic acid); any preparation of difenoxine containing, per dosage unit, a maximum of 0,5 milligram of difenoxine, calculated as base, and a quantity of atropine sulphate equal to at least 5,0 per cent of the quantity of difenoxine, calculated as base, which is present in the mixture.

Dihydrocodeine, *excluding* admixtures containing not more than 2,5 per cent dihydrocodeine.

Dihydromorphine.

Dimenoxadol.

Dimepheptanol.

Dimethylthiambutene.

Dioxaphetylbutyrate.

Diphenoxylate, *excluding* admixtures containing not more than 2,5 milligrams of diphenoxylate calculated as base.

Dipipanone.

Ecgonine, and the esters and derivatives thereof which are convertible to ecgonine and cocaine.

Ethylmethylthiambutene.

Ethylmorphine, *excluding* admixtures containing mot more than 2,5 per cent ethylmorphine.

Etonitazene.

Etorphine.

Etoxeridine.

Fentanyl.

Furethidine.

Hydrocodone (dihydrocodeinone).

Hydromorphinol (14-hydroxydihydromorphine).

Hydromorphone (dihydromorphinone).

Hydroxypethidine.

Isomethadone.

Ketobemidone.

Levomoramide.

Levophenacylmorphan.

Levorphanol.

Mefenorex.

Metazocine.

Methadone.

Methadone—intermediate.

Methorphan, including levomethorphan and racemethorphan, but *excluding* dextromethorphan.

Metadoon-intermediêr.
Metasosien.
Metieldesorfien.
Metieldihidromorfien.
Metielfenidaat en sy derivate.
Metorfaan, insluitende levometorfaan en rasemetorfaan, maar *uitgesonderd* dekstrometorfaan.
Metopoon.
Mirofien (miristielbensielmorfien).
Moramied-intermediêr.
Morferidien.
Morfien, *uitgesonderd* preparate en mengsels van morfien wat hoogstens 0,2 persent morfien, bereken as watervry morfien, bevat, en *uitgesonderd* mengsels waarvan morfien nie deur maklik toepasbare middele herwin kan word nie of nie soveel herwin kan word dat dit 'n gevaar vir die openbare gesondheid inhou nie. (Sien ook Chlorodien).
Morfienmetobromied en ander pentavalente stikstofmorfienderivate.
Morfien-N-oksied en sy derivate.
Nikodikodien.
Nikokodien.
Nikomorfien.
Norasimetadol.
Norkodeïen, *uitgesonderd* mengsels wat hoogstens 2,5 persent norkodeïen bevat.
Norlevorfanol.
Normetadoon.
Normorfien (demetielmorfien of N-gedemetileerde morfien).
Norpipanoon.
Oksikodoon (14-hidroksidihidrokodeïnoon of dihidrohidroksikodeïnoon).
Oksimorfoon (14-hidroksidihidromorfinoon of dihidrohidroksimorfinoon).
Opium, *uitgesonderd* mengsels wat hoogstens 0,2 persent morfien, bereken as watervry morfien, bevat. (Sien ook Chlorodien).
Papawerstrooikonsentraat.
Petidien, petidien-intermediêr A, petidien-intermediêr B en petidien-intermediêr C.
Piminodien.
Piritramied.
Proheptasien.
Properidien.
Propiram.
Rasemoramied.
Rasemorfaan.
Tebakon.
Tebaïen.
Trimeperidien.

## Bylae H

(Bylae 8 by Wet No. 101 van 1965.)

Al die stowwe genoem in hierdie Bylae sluit in—

(*a*) die isomere van die stowwe waar die bestaan van sodanige isomere in die bepaalde chemiese samestellings moontlik is;
(*b*) die esters en eters van die stowwe en die isomere daarvan, waar die bestaan van sodanige esters en eters moontlik is;
(*c*) die soute van die stowwe of die isomere daarvan of van die esters of eters van die stowwe of die isomere daarvan, waar die bestaan van sodanige soute moontlik is;
(*d*) al die preparate en mengsels van die stowwe waar sodanige preparate en mengsels nie uitdruklik uitgesluit word nie.

Bereide opium.
Bufotenien (N, N-dimetielserotonien).
Cannabis en die hele plant of enige gedeelte of produk daarvan.
Diëtieltriptamien [3-(2-(diëtielamino)-etiel)-indool]
Dimetieltriptamien [3-(2-dimetielamino)-etiel)-indool]
Harmalien (3,4-dihidroharmien).
Harmien [7-metoksi-1-metiel-9-pirid (3,4-6)-indool]
Heroïen (diasetielmorfien).
Kokablaar.
Lisergied (lisergiensuurdiëtielamied).
Meskalien (3,4,5-trimetoksifenetielamien).
Psilosibien (4-fosforieloksi-N, N-dimetieltriptamien).
Psilosien (4-hidroksidimetieltriptamien).
Tetrahidrokannabinol.

---

## Bylae I

(Bylae 9 by Wet No. 101 van 1965.)

Amfetamien.
Deksamfetamien.

Methyldesorphine.
Methyldihydromorphine.
Methylphenidate and its derivatives.
Metopon.
Moramide—intermediate.
Morpheridine.
Morphine, *excluding* preparations and admixtures of morphine containing not more than 0,2 per cent morphine, calculated as anhydrous morphine, and *except* admixtures from which morphine cannot be recovered by readily applicable means or cannot be recovered in such a quantity that it would constitute a risk to public health. (See also Chlorodyne.)
Morphine methobromide and other pentavalent nitrogen morphine derivatives.
Morphine-N-oxide and its derivatives.
Myrophine (myristylbenzylmorphine).
Nicocodine.
Nicodicodine.
Nicomorphine.
Noracymethadol.
Norcodeine, *excluding* admixtures containing not more than 2,5 per cent norcodeine.
Norlevorphanol.
Normethadone.
Normorphine (demethylmorphine or N-demethylated morphine).
Norpipanone.
Opium, *excluding* admixtures containing not more than 0,2 per cent morphine calculated as anhydrous morphine. (See also Chlorodyne.)
Oxycodone (14-hydroxydihydrocodeinone or dihydrohydroxycodeinone).
Oxymorphone (14-hydroxydihydromorphinone or dihydrohydroxymorphinone).
Pethidine, pethidine-intermediate-A, pethidine-intermediate-B and pethidine-intermediate-C
Phenadoxone.
Phenampromide.
Phenazocine.
Phencyclidine.
Phendimetrazine.
Phenomorphan.
Phenoperidine.
Pholcodine, *excluding* admixtures containing not more than 2,5 per cent pholcodine.
Piminodine.
Piritramide.
Proheptazine.
Properidine.
Propiram.
Racemoramide.
Racemorphan.
Thebacon.
Thebaine.
Trimeperidine.

---

## Schedule H

(SCHEDULE 8 TO ACT NO. 101 OF 1965.)

All the substances mentioned in this schedule include—

(*a*) the isomers of the substances where the existence of such isomers is possible in the specific chemical compounds;
(*b*) the esters and ethers of the substances and the isomers thereof where the existence of such esters and ethers is possible;
(*c*) the salts of the substances or the isomers thereof or of the esters or ethers of the substances or the isomers thereof, where the existence of such salts is possible;
(*d*) all the preparations and admixtures of the substances where such preparations and admixtures are not expressly excluded.

Bufotenine (N,N-dimethylserotonin).
Cannabis and the whole plant or any portion or product thereof.
Coca leaf.
Diethyltryptamine [3-(2-(diethylamino)-ethyl)-indole].
Dimethyltryptamine [3-(2-(dimethylamino)-ethyl)-indole].
Harmaline (3, 4-dihydroharmine).
Harmine [7-methoxy-1-methyl-9-pyrid (3, 4-6)-indole].
Heroin (diacetylmorphine).
Lysergide (lysergic acid diethylamide).
Mescaline (3, 4, 5-trimethoxyphenethylamine).
Prepared Opium.
Psilocin (4-hydroxydimethyltryptamine).
Psilocybin (4-phosphoryloxy-N, N-dimethyltryptamine).
Tetrahydrocannabinol.

---

## Schedule I

(SCHEDULE 9 TO ACT NO. 101 OF 1965.)

Amphetamine.
Dexamphetamine.

PRINTED FOR THE GOVERNMENT PRINTER, PRETORIA, BY CAPE & TRANSVAAL PRINTERS LTD., CAPE TOWN—B891/15 300.
GEDRUK VIR DIE STAATSDRUKKER, PRETORIA, DEUR KAAP & TRANSVAAL DRUKKERS BPK., KAAPSTAD—B891/15 300.